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ABSTRACT 
Although a number of risk factors for medication-overuse headache (MOH) have been 
identified within the general population, limited research exists examining clinical samples of 
headache sufferers. Further, prior studies have not assessed the relative influence of risk factors 
or their utility in combination.  
As part of an online survey, 164 headache patients completed a demographic 
questionnaire, a diagnostic interview for headache, a measure of headache-related disability, 
measures of psychiatric symptoms, and measures of medication use and substance use. 
Standardized mean differences were used to quantify differences between patients who met 
diagnostic criteria for MOH and those who did not across five domains of predictors 
(demographic characteristics, headache characteristics, psychiatric symptoms, medication use, 
and substance use). The variables within each domain that best discriminated between those who 
met criteria for MOH and those who did not were identified using a classification tree approach 
with Bonferroni corrections. Candidate variables were then entered into a multivariate logistic 
regression to predict MOH status.  
Forty-three of the 164 patients (26.2%) of the sample met diagnostic criteria for MOH. 
Patients with MOH were more disabled by their headaches (mean [SD]: 67.60 [6.00] vs 63.31 
[6.68]) and reported more escape and avoidance behaviors in response to headache pain (14.64 
[5.36] vs 10.44 [6.13]. The use of combination medication for the treatment of headache (60.5% 
vs 33.1%, odds ratio 3.10, 95% confidence interval [CI] 1.51-6.36) was associated with more 
than a threefold risk of MOH. These three variables were forced into a final multivariate model, 
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which differentiated well between the two groups (area under the receiver operating 
characteristic curve = .78; 95% CI .71-.86).  
Based on these results, headache-related disability, fear and avoidance of pain-related 
stimuli, and the use of combination medications for the treatment of headache best predict MOH 
among treatment-seeking headache sufferers. Brief screening measures that assess relevant risk 
factors may be used to aid in the identification of headache patients most likely to have MOH 
and behavioral and cognitive-behavioral interventions may hold promise for the prevention of 
MOH and the reduction of acute medication use among individuals with MOH. 
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I. INTRODUCTION 
1.1 Headache Diagnoses 
Worldwide, 46% of adults suffer from an active headache disorder (Stovner, et al., 2007). 
The International Classification of Headache Disorders 3rd edition-beta version (ICHD-IIIβ) 
classifies headaches not attributable to identifiable organic pathology as primary headaches. The 
most common primary headache disorders are migraine and tension-type headache (TTH), which 
are two of the top three most prevalent medical conditions worldwide (Vos et al., 2012). In 
contrast, headaches deriving from illness or injury (e.g., trauma, surgery, infection, illicit 
substance use, and medication overuse; ICHD-IIIβ) are classified as secondary headaches. 
Primary headaches comprise the large majority of headaches experienced by the population. 
With the exception of the very rare condition of cluster headache, primary headache disorders 
are more prevalent in women than in men across cultures (Stovner et al., 2007), making 
headache a significant women’s health concern. 
A recently published meta-analysis indicates that, migraine affects 11.6% of adults 
worldwide (Woldeamanuel & Cowan, 2017). Migraine attacks typically last between 4 to 72 
hours and are characterized by unilateral pulsating head pain of moderate to severe intensity. 
Migraine may be aggravated by routine physical activity and for diagnosis must produce nausea, 
vomiting, or both photophobia (sensitivity to light) and phonophobia (sensitivity to sound). In a 
significant minority of cases, migraine attacks are preceded by aura, a constellation of temporary 
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focal neurological symptoms that are commonly visual in nature (e.g., seeing spots or zigzag 
lines, blurry vision). Aura symptoms usually develop gradually over 5-20 minutes and last for
less than an hour, after which time the head pain begins (ICHD-IIIβ; Lipton, Scher, 
Silberstein, Liberman, & Bigal, 2008). 
Tension-type headache is the most common type of primary headache, affecting 
approximately 42% of adults worldwide (Stovner et al., 2007). Tension-type headaches may last 
anywhere from 30 minutes to 7 days. Unlike migraine, the pain of TTH is characterized as 
bilateral, pressing or tightening in quality, of mild to moderate severity, and not worsened by 
routine activity (Rasmussen, Jensen, Schroll, & Olesen, 1991). Nausea and vomiting are not 
typically associated with TTH, but photophobia or phonophobia (not both) may accompany these 
headaches, although they are typically of lesser severity compared to that observed in migraine 
(ICHD-IIIβ; Jensen, 2003). 
Cluster headache is a very rare but severe type of primary headache. Approximately 1 in 
1000 people suffer from cluster headache (Fischera, Marziniak, Gralow, & Evers 2008). Left 
untreated, cluster headaches typically last for 15 to 180 minutes. Cluster headache is 
characterized by unilateral, excruciating pain typically of orbital or supraorbital temporal 
distribution (ICHD-IIIβ). Attacks are accompanied by ipsilateral autonomic symptoms (e.g., 
lacrimation, swelling of the orbital socket) and produce restlessness and agitation that often 
manifest as continuous pacing because of the extreme pain severity (Torelli & Manzoni, 2003). 
Individuals who suffer from cluster headache often report a significant personal and 
socioeconomic burden as a result (Jensen et al., 2007).  
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Migraine and other forms of recurrent headache are among the most common and 
disabling disorders of the nervous system (Andlin-Sobocki, Jonsson, Wittchen, & Olesen, 2005; 
Olesen, Gustavsson, Svensson, Wittchen, & Jonsson, 2012; Rasmussen, Jensen, & Olesen, 
1992). Due to the financial costs (Hu, Markson, Lipton, Stewart, & Berger, 1999) conferred to 
both the individual and to society, headache is among the top ten most disabling conditions 
worldwide (Stovner et al., 2007; Vos et al., 2012) and among the top five most disabling 
conditions for women (Stovner, et al., 2007). According to the National Ambulatory Care Survey 
(NAMCS), “pain in the head” was among the top 20 reasons for outpatient doctor’s visits in 
2009 (National Center for Health Statistics [NCHS], 2010), and 7.7 million emergency 
department (ED) visits were attributed to acute headache in 2010 (Mazer-Amirshahi, et al., 
2014). Accordingly, head pain is among the top five leading causes of ED visits, accounting for 
3.1% of ED visits between 2009 and 2010 (Burch, Loder, Loder, & Smitherman, 2015; 
Smitherman, Burch, Sheikh, & Loder, 2013). 
Most frequently, primary headache disorders occur episodically (< 15 days per month); 
however, approximately 3-5% of adults in the general population experience “chronic” headache 
(CH; Castillo, Munoz, Guitera, & Pascual, 1999; Lanteri-Minet et al., 2003; Lu, Fuh, Chen, 
Juang, & Wang, 2001; Stovner, et al., 2007; Wang, et al., 2000; Westergaard, Glumer, Hansen, 
& Jensen, 2014). Chronic headache disorders are those with a frequency of 15 or more headache 
days per month (ICHD-IIIβ). Even though episodic headache (EH) is much more common, 
individuals with CH make up a large percentage of patients seen in U.S. headache clinics 
(Mathew, 1993). Compared to individuals with EH, individuals with CH experience lower 
quality of life, increased disability, reduced work productivity, more frequent and severe 
psychiatric comorbidities, more and longer hospitalizations, and increased medical costs (Buse, 
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Silberstein, Manack, Papapetropoulos, & Lipton, 2012; Lanteri-Minet, Duru, Mudge, & Cottrell, 
2011).  
1.2 Acute Medications as Treatment for Headache 
Headache patients commonly use acute medications in order to relieve the pain and 
disability associated with attacks. As such, headache is among the most common reasons for 
acute pain medication consumption in the general population (Eggen, 1993; Meskunas, Tepper, 
Rapoport, Sheftell, & Bigal, 2006; Zwart, Dyb, Hagen, Svebak, & Holmen, 2003). Acute 
medications prescribed for headache include headache-specific agents (e.g., ergotamine 
derivatives and triptans), dopamine antagonists (e.g. metochloproamine and prochlorperazine), 
nonspecific medications (e.g. nonsteroidal anti-inflammatory drugs [NSAIDS]), opioids (e.g., 
codeine and hydrocodone), barbiturates (e.g., butalbital), and combination analgesics (e.g. 
aspirin, acetaminophen, and caffeine combinations; Silberstein, Freitag, & Bigal, 2008). 
Ergotamine was the first acute medication developed specifically for the treatment of 
headache.  Ergotamine was the treatment-of-choice for migraine until the late 1980s and early 
1990s when triptans were introduced and quickly supplanted ergotamine due to superior efficacy 
and more favorable side effect profiles. Current consensus guidelines recommend triptans as 
first-line options for the treatment of headache (Marmura, Silberstein, & Schwedt, 2015; 
Silberstein et al., 2000). As a result, triptans accounted for 80% of the over 6 million 
prescriptions written for acute migraine medications in outpatient clinics in 2009 (NCHS, 2010). 
Although triptans are frequently prescribed by headache specialists, prescription practices vary 
considerably by setting. According to recent analyses of ED prescription practices, triptans are 
prescribed in few (<2%) ED visits for headache. Instead, opioids (22.8% – 30.5%) and NSAIDS 
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(16.9% - 31.4%) were far more likely to be prescribed in the ED (Mazer-Amirshahi et al., 2014; 
McCarthy & Cowan, 2015). Despite consensus guidelines that recommend opioid analgesics and 
butalbital not be used as first-line agents (Loder, Weizenbaum, Frishberg, & Silberstein, 2013; 
Silberstein et al., 2000), opioids were more frequently prescribed to treat headache during ED 
visits in 2010 (35.0%) than in 2001 (20.6%; Mazer-Amirshahi et al., 2014).  
Although acute headache medications are vital to the management and treatment of 
headache, their overuse is frequently associated with CH and may lead to a gradual 
transformation from EH to CH termed “chronification” (Lipton, 2009; Mathew, 1998). 
Approximately 30% of individuals with CH (Scher, Midgette, & Lipton, 2008) and more than 
70% of individuals treated for CH in headache clinics (Bigal, Rapoport, Sheftell, Tepper, & 
Lipton, 2004) overuse acute headache medications. On average, individuals with CH use acute 
headache medications on 18.3 days per month, and 23% report taking acute medications on a 
daily basis (Scher, Lipton, Stewart, & Bigal, 2010).  
1.3 Classification of Medication-Overuse Headache 
Frequent use of acute headache medications may produce a form of secondary headache 
referred to as medication-overuse headache (MOH), which was first described in the 1950s and 
1960s when chronic intractable headache was observed among frequent users of ergotamine 
(Peters & Horton, 1951; Horton & Peters, 1963). Medication-overuse headache currently is 
defined as CH (headache frequency > than 15 days a month) coinciding with regular overuse of 
acute headache medications. “Overuse” is quantified as use on 10 or more days per month for 
triptans, ergotamine, and combination analgesics or 15 or more days per month for simple 
analgesics and combinations of acute medications, for more than 3 months. Headache typically, 
5 
 
but not always, remits after overuse stops (ICHD-IIIβ), which may require inpatient 
hospitalization for supervised medication withdrawal. Table 1 displays the ICHD-IIIβ criteria for 
MOH.  
Table 1. The International Classification of Headache Disorders (ICHD-3β) Criteria for 
Medication-Overuse Headache 
A. Headache occurring on ≥15 days per month in a patient with a pre-existing 
headache disorder. 
B. Regular overuse for >3 months of one or more drugs that can be taken for acute, 
and/or symptomatic treatment of headache. 
1. Regular intake of ergotamine, triptans, opioids, or combination analgesics on 
≥10 days per month for >3 months. 
2. Regular intake of simple analgesics on ≥15 days per month for >3 months. 
3. Regular intake of any combination of ergotamine, triptans, simple analgesics, 
NSAIDS, and/or opioids on a total of ≥ 10 days per month for >3 months 
without overuse of any single drug or drug class alone. 
C. Not better accounted for by any other ICHD-3 diagnosis.  
Note. International Headache Society. (2013). The International Classification of Headache 
Disorders, 3rd ed. (beta version). Cephalalgia, 33, 629-808.  
1.4 Medication-Overuse Headache: Prevalence and Epidemiology 
The prevalence of MOH is 1-2% within the general population (Colas, Munoz, 
Temprano, Gomez, & Pascual, 2004; Diener & Limmroth, 2004; Stovner et al., 2007; 
Westergaard et al., 2014). Despite its relatively low prevalence in population studies, MOH is 
disproportionately common in pain clinics and specialty headache centers. Schmid and 
colleagues (2013) reported that 29% of adult pain patients referred to an interdisciplinary pain 
clinic met diagnostic criteria for MOH. Furthermore, up to 25% of adult headache patients in 
Europe (Zeeberg, Olesen, & Jensen, 2006) and 50% of adult patients in the United States 
(Meskunas et al., 2006) present with MOH. Estimates of the mean duration of primary headache 
among those with MOH are 14.9 – 20.4 years, and the mean duration of medication overuse is 
4.0 – 10.3 years (Deiner & Dahlof, 1999; Dong et al., 2015). Overall, MOH is more common in 
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women than in men (Bigal et al., 2004; Jonsson, Hedenrud, & Linde, 2011; Straube et al., 2010), 
and mirrors the gender difference in migraine prevalence. It is unclear whether women are 
actually more likely than men to misuse their medication, or whether gender difference in MOH 
are a function of disproportionate headache prevalence (Burch et al., 2015; Westergaard et al., 
2014). Medication-overuse headache is most prevalent among middle-aged individuals of both 
genders (D’Amico, Grazzi, Usai, Rigamonti, Curone, & Bussone, 2005; Jensen & Bendtsen, 
2008; Westergaard et al., 2014) with mean age of onset at 45 years (Colas et al., 2004). Because 
MOH onset often occurs during years of peak productivity, MOH imparts a significant burden on 
patients and society.  
1.5 Disability Associated with Medication-Overuse Headache 
Medication overuse headache was recently identified as the 18th leading cause of 
disability worldwide (Vos et al., 2015). Both the individual and society are negatively impacted 
by MOH due to lost productivity, elevated disability, increased medical costs, and a high burden 
on health care services (D’Amico et al., 2005; Linde et al., 2012). Moreover, MOH is 
substantially more disabling than other forms of headache. Individuals with MOH experience 
considerable work-related impairment, as the number of workdays lost by MOH patients is 
nearly six times higher than the number of workdays lost by those with episodic migraine (EM; 
Raggi et al., 2015). The annual personal cost of MOH is 3 times higher than the personal cost of 
migraine and more than 10 times higher than that of TTH (Linde et al., 2012). Some evidence 
suggests that MOH may result in even greater reductions in quality of life than other forms of 
CH (Lanteri-Minet et al., 2011). For these reasons, some have asserted that MOH is prevalent 
and among the most costly neurological condition known (Russell & Lundqvist, 2012). 
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1.6 Treatment of Medication-Overuse Headache 
The withdrawal of overused medications, either abruptly or via gradual tapering, is the 
treatment-of-choice for MOH (Evers & Jensen, 2011; Obermann, Bartsch, & Katsarava, 2006). 
Headache frequency gradually declines over the days and weeks following withdrawal of the 
overused medication (Katsarava, Fritsche, Diener, & Limmroth, 2001; Relja, Granato, Bratina, 
Antonello, & Zorzon, 2006). The withdrawal of opioids, barbiturates, and benzodiazepines are 
often associated with significant withdrawal symptoms (e.g., worsening of headache, nausea, 
vomiting, restlessness, anxiety, and nervousness); therefore, gradual withdrawal may be the best 
option for patients overusing these agents. Abrupt withdrawal is the treatment-of-choice for 
patients who misuse triptans, ergots, combination analgesics, simple analgesics, and NSAIDs, as 
severe withdrawal symptoms are uncommon with these medications (Evers & Jensen, 2011). 
Withdrawal symptoms typically last for 2-14 days, and the duration of withdrawal symptoms is 
typically shorter for patients who overused triptans in comparison to those who overused 
ergotamine or NSAIDs (Katsarava et al., 2001; Rabe et al., 2013). Initiation of a prophylactic 
regimen in conjunction with withdrawal of the acute medication is often associated with better 
outcomes in comparison to acute medication withdrawal alone (Chiang, Schwedt, Wang, & 
Dodick, 2016). For example, initiation of a prophylactic regimen in conjunction with withdrawal 
of the acute medication is associated with significant reductions in headache frequency and 
improvements in quality of life, headache-related disability, anxiety, and depression (Bendtsen et 
al., 2014; Wallasch & Kropp, 2012; Zebenholzer, Thamer, & Wober, 2012).  
 
 
8 
 
1.7 Pathophysiology of Medication-Overuse Headache 
The pathophysiology of MOH remains unclear. Given that MOH can be caused by the 
excessive use of any class of migraine-specific or non-specific acute medication, it is unlikely 
that MOH is attributable to the action of any specific agent. Rather, it seems more likely that 
acute pain medications used to treat headache share a common mechanism that is capable of 
producing headache chronification (Srikiatkhachorn, le Grand, Supornsilpchai, & Storer, 2014). 
In line with this hypothesis, neuronal hyperexcitability in the cerebral cortex and trigeminal 
system following the excessive use of acute pain medications, has been identified as a 
pathophysiological mechanism that may underlie central sensitization and cortical spreading 
depression (CSD; an analog for migraine aura).  
Prolonged exposure to opioids may produce allodynia and hyperalgesia for long periods 
after the discontinuation of the medication (Ali, 1986; Arner & Meyerson, 1988; De Felice & 
Porreca, 2009; Johnson, Hutchinson, Williams, & Rolan, 2013). Calcitonin gene-related peptide 
(CGRP) plays a prominent role in initiating vasodilation of the intracranial blood vessels and is 
implicated in the pathogenesis of migraine (De Felice & Porreca, 2009) and increased expression 
of CGRP has been observed in the dorsal root ganglia following chronic administration of 
opioids (Belanger, Ma, Chabot, & Quirion, 2002; Ma, Zheng, Kar, & Quirion, 2000). Therefore, 
changes in the expression of CGRP may play a key role in the pronociceptive neural adaptations 
associated with MOH. In addition to changes in the expression of CGRP, sustained exposure to 
opioids is also associated with enhanced glutamate release (Gardell et al., 2002), expansion of 
cutaneous receptive fields, lower thresholds of dura-sensitive medullary dorsal horn neurons 
(Okada-Ogawa, Porreca, & Meng, 2009), and activation of toll-like receptor-4 on glial cells (De 
Felice & Porreca, 2009; Johnson et al., 2013). Although hyperalgesia is more commonly 
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associated with opioid medications, prolonged exposure to triptans can also produce changes in 
trigeminal pain nociceptive systems. Enduring but reversible cutaneous tactile allodynia has been 
observed in rats following chronic triptan administration. This change is associated with 
increased levels of CGRP in afferent trigeminal ganglionic (TG) neurons (De Felice et al., 
2010b) and increased expression of nitric oxide synthase in the trigeminal neurons that innervate 
the dura of rats (DeFelice et al., 2010a). Considered together, this evidence suggests that the 
overuse of opioids and triptans can produce a persistent proinflammatory state and long-lasting 
pronociceptive adaptation in trigeminal primary afferent neurons located in the peripheral 
nervous system. 
In addition to sensitization of neurons in the trigeminal system, serotonergic dysfunction 
has been implicated in the development of MOH as well as the affective disorders that are 
frequently comorbid with headache and (Atasoy, Atasoy, Unal, Emre, & Sumer, 2005; Hagen, 
Linde, Steiner, Stovner, & Zwart, 2012). Triptans are presumably effective due to their action as 
agonists on the serotoninergic system. Triptans act on 5-HT1B/1D receptors which primarily exert 
an inhibitory effect. The acute and systematic administration of triptans decreases 5-HT 
synthesis in brain areas such as the dorsal raphe nucleus. However, chronic administration of 
triptans produces the paradoxical effect of increasing 5-HT synthesis. Potential mechanisms for 
this increase in 5-HT synthesis include a down-regulation or desensitization of 5-HT1 receptors 
and/or an unmasking of excitatory triptan-sensitive 5-HT receptors (Dobson, Tohyama, Diksic, 
& Hamel, 2004).  Like triptans, acetaminophen acts on the serotoninergic system. However, 
acetaminophen acts on 5-HT2A receptors. Unlike to 5-HT1 receptors, activation of 5-HT2A 
receptors is associated with increased neuronal excitability. The acute administration of 
acetaminophen is associated with significant increases of 5-HT and a decrease in the number of 
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5-HT2 receptors available in the cerebral cortex (Pini, Sandrini, & Vitale, 1996). However, 
chronic administration of acetaminophen to rats has been found to increase the frequency of CSD 
and CSD-evoked increases of 5-HT2A serotonin receptor expression in the cerebral cortex and 
trigeminal nucleus caudalis (Supornsilpchai, le Grand, & Srikiatkhachorn, 2010a & 
Supornsilpchai, le Grand, & Srikiatkhachorn, 2010b).  
Impairment of the endogenous 5-HT dependent pain modulation system may underlie the 
cortical sensitization and pain facilitation associated with MOH. Animal models suggest that 
decreased availability of 5-HT is associated with upregulations in the expression of 
pronoiceptive 5-HT2A receptors in the cortex and trigeminal system, increased CGRP expression 
in the TG, and increase susceptibility to CSD (Le Grand, Saengjaroentham, Supronsilpchai, & 
Srikiatkhachorn, 2010; Maneepak, le Grand, & Srikiatkhachorn, 2009; Saengjaroentham, 
Supornsilpchai, Srikiatkhachorn, le Grand, 2012;  Supornsilpchai, le Grand, & Srikiatkhachorn, 
2010a; Supornsilpchai, Sanguanrangsirikul, Maneesri, & Srikiatkhachorn, 2006). These findings 
suggest that the chronic administration of acetaminophen or triptans may negatively impact 
central pain modulation systems by either decreasing nociceptive inhibition or by increasing 
nociceptive facilitation.  
In summary, more research is needed in order to better understand the pathophysiology of 
MOH; however, chronic exposure to acute headache medications such as opioids, 
acetaminophen, and triptans is associated with increased neuronal excitability in the trigeminal 
system and cerebral cortex. Increased neuronal excitability in the cortex may increase 
susceptibility to CSD; whereas, increased excitability of trigeminal neurons may facilitate 
peripheral and central sensitization. Such neuronal excitability following the overuse of acute 
headache medications is thought to be secondary to impairment of serotoninergic pain 
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modulation systems that exert a strong influence on the trigeminal system. The depletion of 5-
HT following the excessive use of acute headache medication may be driven at least in part by 
upregulation of pronociceptive 5-HT2A receptors that increase susceptibility to CSD. 
Furthermore, low 5-HT levels may also increase the release of CGRP and the subsequent 
sensitization of trigeminal nociceptors. Therefore, impairment of the serotonin-dependent pain 
modulation systems subsequent to chronic headache medication may be central to increased pain 
sensitivity and MOH.  
1.8 Medication Use Patterns Associated with Medication-Overuse Headache 
All acute medications used for the treatment of headache are capable of causing MOH 
(ICHD-IIIβ; Obermann et al., 2006), but as prescription practices have changed so have the rates 
of MOH caused by various medications. Meskunas and colleagues (2006) randomly reviewed 
the charts of patients seen at a single headache center during the years of 1990, 1995, 2000, and 
2005. Between 1990 and 2005 MOH attributed to ergotamine and combination analgesics 
declined significantly (18.6% to 0% for ergotamine and 42.2% to 13.6% for combination 
analgesics). Simultaneously, frequency increased significantly for MOH attributed to the overuse 
of triptans (0% to 21.6%), simple analgesics (8.8% to 31.8%), and for combinations of acute 
medications (9.8% to 22.7%). Although there was a decrease in MOH associated with opioid 
overuse during this same period (18.6% to 9.1%), the trend was not statistically significant.  
Individuals with CH are more likely to use opioid-combination analgesics in comparison 
to those with EH or no headache (Bigal & Lipton, 2008; Scher et al., 2010). The use of opioids 
for the treatment of headache is controversial. Evidence suggests that opioids are likely to 
sensitize the central nervous system to pain and increase the risk of MOH (Bigal & Lipton, 2008; 
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Johnson et al., 2013). Compared to individuals using acetaminophen to treat their migraines, 
individuals using opioids are at an increased risk for migraine chronification (Bigal, Serrano, 
Buse, Scher, Stewart, & Lipton, 2008; Scher et al., 2010). The management of headache via 
opiates is not recommended as a first-line treatment option due to relatively lower efficacy in 
comparison to a number of other acute medications as well as a number of adverse effects 
including tolerance, dependence, and addiction (Levin, 2014). Further, the critical dose of 
exposure likely to produce a transition from episodic to chronic headache is low (approximately 
8 days per month; Bigal & Lipton, 2008).  Despite these adverse effects, opioids are frequently 
prescribed in clinical practice, particularly in ED settings (Mazer-Amirshahi et al., 2014; 
McCarthy & Cowan, 2015).  
Despite the efficacy and cost-effectiveness of triptans (Asseburg, Peura, Oksanen, 
Turunen, Purmonen, & Martikainen, 2012; Thorlund et al., 2014), a large proportion (43%) of 
individuals with chronic migraine (CM) overuse them (Ferrari et al., 2007). As a result, triptans 
are frequently implicated in the development of MOH. Medication-overuse headache may 
develop more quickly and at a lower dosage for individuals who are prescribed triptans in 
comparison to individuals who are prescribed other acute headache medications. The mean 
critical duration of overuse (calculated by subtracting the duration of MOH from the duration of 
medication overuse) is shorter for triptans (1.7 years) than for ergots (2.7 years) and simple 
analgesics (4.8 years). Among patients with MOH, the mean monthly number of doses necessary 
to produce MOH is lower for triptans (18 doses per month) compared to ergots (37) and simple 
analgesics (114; Limmroth, Katsarava, Fritsche, Przywara, & Diener, 2002).  
Simple analgesics, NSAIDs, and combination analgesics are frequently used to treat 
headache because they are affordable and readily available over-the-counter (Dong et al., 2015; 
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Zwart, Dyb, Hagen, Svebak, Stovner, & Holmen, 2004), particularly outside of the United States 
where triptans are less likely to be prescribed. For instance, two-thirds of a Spanish sample with 
MOH reported the use of simple analgesics alone or in combination with ergotamine (Colas et 
al., 2004), whereas combination analgesics were most commonly overused by Chinese patients 
with MOH (Dong et al., 2015). In the United States, individuals with tension-type headache TTH 
frequently use over-the-counter medications such as NSAIDS (Lyngberg, Rasmussen, Jorgensen, 
& Jensen, 2005). NSAIDs have been found to exert a dose-dependent protective effect such that 
NSAIDs are associated with a decreased risk for MOH among individuals with low to 
intermediate headache frequency (Bigal & Lipton, 2009; Bigal, et al., 2008; Scher at al., 2010), 
but increased risk for chronification and MOH among individuals who have 10 or more 
headaches per month (Bigal & Lipton, 2009). Consequently, patients with chronic tension-type 
headache (CTTH) are at an increased risk for MOH.  
Analgesics are used and overused in attempts to treat a wide variety of chronic pain 
conditions; therefore, the question has been raised whether the frequent use of analgesics can 
induce CH in previously headache-free individuals. Medication-overuse headache is most 
frequently diagnosed in patients with a prior history of migraine (Radat et al., 2008; Zwart et al., 
2003) and to a lesser degree TTH (Silberstein, Lipton, & Sliwinski, 1996). Contradictory to long-
held clinical lore, patients with cluster headache may also develop MOH; however, cluster 
headache patients with a personal or family history of migraine appear to be at a much greater 
risk for MOH than individuals with no personal or family history of migraine (Paemeleire, Evers, 
& Goadsby, 2008). Although individuals with a history of primary headache may experience 
chronification following the overuse of analgesics prescribed for conditions other than headache, 
MOH is very rare among individuals without a history of primary headache. For example, 
14 
 
patients with no prior history of primary headache who consumed large amounts of pain 
medications for the treatment of arthritis and irritable bowel syndrome did not show an increased 
incidence of CH (Bahra, Menon, & Goadsby, 2003; Lance, Parkes, & Wilkinson, 1988; 
Wilkinson, Becker, & Heine, 2001). Schmid and colleagues (2013) found that interdisciplinary 
pain patients with a history of primary headache had 13.1 times greater odds of having MOH 
than patients without a history of primary headache. However, individuals with primary 
headache who are diagnosed with comorbid chronic musculoskeletal pain or gastrointestinal 
complaints appear to be at greater risk for MOH compared to individuals without comorbid pain 
or gastrointestinal complaints (Hagen et al., 2012). This increased risk may be in part attributable 
to greater access to pain medications, but it appears unlikely that individuals with no prior 
history of headache will develop headache “de novo” as a result of medication overuse for 
another condition.  
1.9 Modifiable Risk Factors for Medication-Overuse Headache 
In addition to medication-taking behaviors, a variety of other factors are associated with 
increased risk for MOH. Although some risk factors such as gender and headache diagnosis are 
not modifiable, others are modifiable and should be emphasized because they are amenable to 
intervention. Modifiable risk factors include low socioeconomic status (SES), high body mass 
index (BMI), substance use and abuse, and mood and anxiety disorders. 
Socioeconomic status is strongly associated with MOH. Compared to individuals without 
headache and patients with other headache diagnoses, patients with MOH are more likely to 
report a secondary school education or lower, be unemployed, and have a lower household 
income (Dong et al., 2015; Jonsson et al., 2011).  Despite a clear connection between MOH and 
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SES, the direction of the relationship is unclear, and longitudinal research is needed to determine 
whether those with low socioeconomic status are more likely to develop MOH or whether MOH 
instead limits their professional and economic advancement.  
Maladaptive health behaviors and lifestyle factors are frequently associated with 
headache chronification (Bigal et al., 2008; Scher et al., 2008; Westergaard, Glumer, Hansen, & 
Jensen, 2016). Among individuals with MOH, 21.9% are obese (Body Mass Index [BMI] ≥30), 
and individuals with MOH are more likely to be obese than headache-free controls, those with 
EM, and individuals with chronic headache without medication overuse (Straube et al., 2010; 
Westergaard, Glumer, Hansen, & Jensen, 2016). Thus, modifiable health behaviors such as diet 
and physical activity may play a role in the development of obesity and MOH. Hagen and 
colleagues (2012) provided support for this hypothesis when they found that physical inactivity 
more than doubled (OR = 2.7) the risk for MOH. Although some people with MOH may adopt a 
sedentary lifestyle in an attempt to avoid headache pain, prospective data suggest that obesity 
most often precedes increased headache frequency (Bigal, Liberman, & Lipton, 2006).    
In addition to SES and health behaviors, substance-use has also been explored in relation 
to MOH. Limited evidence suggests that MOH patients are more likely than migraineurs to 
report a personal history of substance abuse or dependence (OR = 7.6) and a family history of 
alcohol or drug use disorders (OR = 2.8). Although dependence is seen among who overuse 
triptans, dependence was most common among individuals who overused opioids (Radat et al., 
2005). Specific substances linked to an increased risk for MOH include prescription medications 
and tobacco. Medication-overuse headache patients were also more likely than headache-free 
controls and individuals with EM to be active smokers (Straube et al., 2010). Further, a 
longitudinal population-based study found that individuals who used anxiolytics such as 
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benzodiazepines were at a five times greater odds (OR = 5.2) and smokers were at a more than 
doubled odds for developing MOH, in comparison to individuals who did not use these 
substances (Hagen et al., 2012). By comparison, alcohol use and illicit drug use do not appear to 
be associated with an increased risk for the development of MOH (Hagen et al., 2012; 
Westergaard et al., 2016), likely because these substances trigger headache for many individuals. 
Notably, alcohol consumption is frequently lower among headache patients in comparison to 
headache-free controls (Straube et al., 2010).  
Comorbid psychiatric disorders are reported by a large majority (84%) of patients with 
MOH (Wallasch & Kropp, 2012). Compared to migraineurs who did not misuse acute headache 
medications, MOH patients are more likely to suffer from major depressive disorder (OR  = 
21.8), generalized anxiety disorder (OR = 6.0), panic disorder with or without agoraphobia (OR 
= 12.1), and social phobia (OR = 4.3; Radat et al., 2005). Thus, symptoms of anxiety and 
depression may act as risk factors for headache chronification and may predict inadequate 
response to acute headache medications. Indeed, a longitudinal population-based study found 
that individuals with elevated symptoms of anxiety and depression were at nearly five times 
greater odds (OR = 4.7) of developing MOH than individuals who were not anxious or depressed 
(Hagen et al., 2012). Findings from treatment studies indicate that symptoms of anxiety and 
depression are reduced in MOH patients who undergo inpatient treatment that includes 
detoxification and initiation of a preventive headache medication (Zebenholzer et al., 2012). 
Similar results have been found with outpatient treatment studies, as the number of patients with 
depression anxiety decreased by 50.7% and 27.1%, respectively (Bendtsen et al., 2014). Taken 
together, these findings suggest that symptoms of anxiety and depression are closely tied to 
medication overuse and may influence pain coping abilities. Both psychiatric symptoms and 
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chronic pain can increase an individual’s perception of and focus on pain. As a result, individuals 
with headache may become fearful of headache pain and increase their analgesic consumption in 
an attempt to avoid the experience of pain.  
Despite strong evidence that anxiety and depression are associated with MOH, there is a 
paucity of research examining the role of psychological variables specifically pertaining to the 
experience of pain, particularly cognitive appraisals of pain such as fear and anxiety. According 
to the fear-avoidance model of chronic pain (Vlaeyen & Linton, 2000), when pain is interpreted 
as non-threatening, individuals continue engagement in daily activities and functional recovery is 
facilitated. However, when pain is interpreted as threatening, individuals may begin to fear pain 
and engage in escape and avoidance behaviors. In the case of CH, it is not usually possible to 
avoid pain entirely; however, headache patients are often instructed to take headache medication 
as early as possible in the headache episode. In the short-term, hypervigilance and the avoidance 
of pain are adaptive, and the patient is reinforced both negatively (i.e., the headache is prevented) 
and positively (i.e., the patient is able to engage in daily activities) for taking headache 
medication at the first sign of headache. However, prolonged hypervigilance may prompt 
avoidance of physiological sensations and contexts actually unrelated to the experience of 
headache. As a result, repeated avoidance of headache-related stimuli may have the paradoxical 
long-term effect of increasing pain sensitivity, health care utilization, suffering, and disability 
(Asmundson, Norton, & Veloso, 1999; Black, Fulwiler, & Smitherman, 2015; McCracken & 
Dhingra, 2002; Norton & Asmundson, 2004; Vlaeyen, Snijders, Boeren, & van Eek, 1995). 
Headache sufferers frequently endorse high levels of pain-related anxiety and fear (Black et al., 
2015). As a result, these individuals may begin to engage in a maladaptive pattern of avoidance 
that manifests as overuse of acute headache medications (Asmundson, Wright, Norton, & 
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Veloso, 2001) and increased headache frequency (Black et al., 2015).  Furthermore, a recent 
study of migraineurs found that FOP accounted for more variance in disability than gender, 
anxiety, and depression combined (Black et al., 2015). In light of these findings, FOP may act as 
a risk factor for MOH, but it remains under-researched in comparison to other variables.   
1.10 Aims of the Present Study 
The goal of the present study is to identify demographic, headache, psychiatric, 
medication use, and substance use variables jointly associated with MOH in a population of 
adults seeking treatment for primary headache disorders. A large body of research examining the 
prevalence and predictors of MOH makes clear that gender, headache diagnosis, SES, BMI, 
substance use, anxiety, and depression are independent risk factors for MOH (Dong et al., 2015; 
Hagen et al., 2012; Jonsson et al., 2011; Schmid et al., 2013; Straube et al., 2010). However, 
existing research has not empirically examined the comparative importance of these risk factors, 
and the overwhelming majority of research on MOH-related variables has been conducted 
among population samples drawn from outside of the United States. While these endeavors have 
increased our understanding of MOH, a strong need remains to investigate associated factors 
comparatively and among clinical samples given their disproportionate use of healthcare services 
and prevalence among headache specialty clinics (25-50% of patients; Meskunas et al., 2006; 
Zeeberg et al., 2006). Thus, the present study utilized treatment-seeking headache patients and a 
statistical approach that permits comparative and combinatorial analyses of variables that best 
predict MOH status. The current study serves not only to identify variables most strongly 
associated with MOH among treatment-seeking headache patients in the United States, but to 
inform the development and refinement of MOH assessment tools. Finally, the current study aids 
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future MOH prevention and intervention efforts by focusing on modifiable risk factors that are 
amenable to change.    
1.11 Goals & Hypotheses 
The following goals and hypotheses were proposed:  
Study Goal 1:  Determine the demographic, headache-related, psychiatric, medication-use, and 
substance abuse variables that best differentiated individuals with MOH from treatment-seeking 
headache sufferers who did not meet criteria for MOH. 
Hypothesis 1a: Compared to other demographic variables, gender would be most strongly 
associated with MOH, as women would be more likely to endorse MOH than men. 
 Hypothesis 1b: Compared to other headache-related variables, headache characteristics 
commonly associated with migraine would be most strongly associated with MOH, as 
patients who reported headache duration of 4 hours or longer, patients who endorsed 
nausea during headache episodes, and patients who were sensitive to light and sound 
during headache episodes would be more likely to endorse MOH than patients who did 
not report these symptoms.  
Hypothesis 1c: Compared to other headache medications, the use of opioids would be 
most strongly associated with MOH, as individuals who used opioids for the treatment of 
headache pain would be more likely to endorse MOH relative to patients who used other 
medications for the treatment of headache.  
Hypothesis 1d: Compared to other psychiatric variables, FOP would be most strongly 
associated with MOH, as patients who endorsed high FOP would be more likely to meet 
diagnostic criteria for MOH than patients with low FOP. 
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Hypothesis 1e: Compared to other substance abuse variables, the use or misuse of 
opioids, anxiolytics, and sedatives would be most strongly associated with MOH, as 
patients who used or misused opioids, anxiolytics, and sedatives would be more likely to 
meet diagnostic criteria for MOH than patients who did not overuse opioids, anxiolytics, 
and sedatives.  
Study Goal 2: Identify the combination of predictor variables that best differentiated MOH 
patients from treatment-seeking headache sufferers who did not meet criteria for MOH.  
Hypothesis 2a: Gender, headache characteristics associated with migraine (headache 
duration ≥ 4 hours, nausea, photophobia, and phonophobia), the use of opioids for 
headache pain, FOP, and the use or misuse of opioids, anxiolytics, and sedatives would 
each be uniquely associated with MOH status.  
Hypothesis 2b: In conjunction, gender, headache characteristics associated with migraine 
(headache duration ≥ 4 hours, nausea, photophobia, and phonophobia), the use of opioids 
for headache pain, FOP, and the use or misuse of opioids, anxiolytics, and sedatives 
would best differentiate MOH patients from treatment-seeking headache sufferers who 
did not meet criteria for MOH.
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2. METHODS 
2.1 Participants 
Participants were patients treated for headache at Oxford Neurology Clinic within the last 
six years. Oxford Neurology Clinic is located in Oxford, Mississippi and provides care to 
patients with a variety of diseases of the nervous system, including headache. The clinic offers 
an array of services including consultation and management of primary headache disorders, and 
our lab has an existing collaborative research relationship with the owner and chief neurologist, 
Dr. Malcolm Roland, who is board-certified in both neurology and sleep medicine. Participants 
were at least 18 years of age and had a previously documented diagnosis of migraine, TTH, or 
cluster headache. Assuming a medium to large effect size (OR = 3.14), a power level of 0.80, 
and an alpha level of 0.05, a total sample size of 162 was required (Faul, Erdfelder, Buchner, & 
Lang, 2009). 
2.2 Materials 
2.2.1 Demographic Questionnaire 
 The Demographic Questionnaire was composed of a number of questions assessing basic 
information such as age, gender, education, socioeconomic status, height, and weight. This 
measure can be found in Appendix A.  
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 2.2.2 Structured Diagnostic Interview for Headache – 3 
The Structured Diagnostic Interview for Headache – 3 (SDIH-3; Andrew, Penzien, Rains, 
Knowlton, & McAnulty, 1992; Smitherman, Penzien, Rains, Nicholson, & Houle, 2014) is a 
computer-administered instrument designed to determine the presence of primary headache 
disorders based on the diagnostic criteria set out by the ICHD-IIIβ (2013). The included 21 items 
afforded differential diagnosis of primary headache disorders, while also providing qualitative 
data about headache type, frequency, pain intensity, and duration. Further, the instrument 
provided information about the experience of aura and cluster headaches, and was used to assess 
secondary causes such as head injury or trauma and medication overuse. For the purpose of this 
study, questions related to headache disability and headache triggers were omitted as disability 
was addressed in a subsequent measure and headache triggers were not relevant to the objectives 
of the present study. This measure can be found in Appendix B.   
2.2.3 Headache Medication Use Questionnaire 
 Headache medication use (e.g. NSAIDS, triptans, and antiepileptics) and days per month 
using each headache medication were of particular interest. Medication use data was obtained 
using items included as part of the American Migraine Prevalence and Prevention (AMPP) study 
(Lipton, Serrano, Nicholson, Buse, Runken, & Reed, 2013). Respondents were asked to endorse 
which headache medications they used, the number of days per month of use, and the duration 
each medication had been used at the current frequency. Given that several preventive 
medications commonly prescribed for the treatment of headache were originally developed for 
the treatment of other conditions (e.g. antidepressants and antiepileptics), participants were asked 
to specify whether they were taking each medication for the treatment of headache. Acute and 
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preventive medications commonly used for headache were listed in the questionnaire by both 
brand and generic names. Acute medications classes included commonly used NSAIDS and 
simple analgesics, ergotamine derivatives, triptans, opioids, and combination analgesics. 
Preventive medication classes included antidepressants, antiepileptics, beta-blockers, and 
onabotulinumtoxinA (Botox). This measure can be found in Appendix C. 
2.2.4 Headache Impact Test-6 
 The Headache Impact Test-6 (HIT-6; Kosinski et al., 2003) is a 6-item self-report 
measure of the impact of headache on an individual’s functioning. The instrument addresses how 
social functioning, cognitive functioning, and psychological distress are affected by headache. 
Each question requires the respondent to provide an estimate of frequency of impairment (over 
the last 4 weeks) on a 5-point Likert-type scale ranging from “never” to “always”. Scores range 
from 36 to 78 and provide a basis for categorizing headache-related disability into 4 levels of 
severity: little impact (scores ≤ 49), some impact (50-55), substantial impact (56-59), and very 
severe impact (scores ≥ 60). The HIT-6 has shown good internal consistency (α= 0.90) and test-
retest reliability (r = 0.78) as well as discriminant validity across headache diagnostic groups 
(Kosinski et al., 2003). This measure can be found in Appendix D. 
2.2.5 Patient Health Questionnaire-9 
The Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001) is a 9-
item self-administered measure of depression severity based on DSM-IV diagnostic criteria. 
Each question requires the respondent to provide an estimate of frequency of depressive 
symptoms (over the past two weeks) on a 4-point Likert-type scale. Each item is rated from 0 
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(not at all) to 3 (nearly every day). Scores range from 0 to 27 and provide a basis for categorizing 
depressive symptoms into 4 levels of severity. Scores of 5, 10, 15, and 20 represent mild, 
moderate, moderately severe, and severe depression, respectively. The PHQ-9 has shown good 
construct validity (Kroenke et al., 2001), as well as adequate internal consistency pre- and post-
treatment (α = .74 and .81) and convergent/divergent validity (Titov, Dear, McMillan, Anderson, 
Zou, & Sunderland, 2011). Furthermore, meta-analytic data indicate that the PHQ-9 is externally 
valid and able to correctly identify (sensitivity = 0.80) and rule-out (specificity = 0.92) major-
depressive disorder across a wide range of settings and populations (Gilbody, Richards, Brealey, 
& Hewitt, 2007). This measure can be found in Appendix E.  
2.2.6 Generalized Anxiety Disorder 7-Item Scale 
The Generalized Anxiety Disorder 7-Item Scale (GAD-7; Spitzer, Kroenke, Williams, & 
Lowe, 2006) is a seven item self-administered measure of anxiety symptoms. Each item requires 
respondents to rate the frequency of anxiety symptoms (over the past two weeks) on a 4-point 
Likert-type scale that ranges from 0 (not at all) to 3 (nearly every day). Scores range from 0 to 21 
and scores of 5, 10, and 15 represent mild, moderate, and severe anxiety symptoms, respectively. 
The GAD-7 has excellent internal consistency (α= 0.92) and test-retest reliability (r = 0.83), as 
well as convergent, construct, criterion, procedural, and factorial validity for the diagnosis of 
generalized anxiety disorder (Spitzer et al., 2006). The GAD-7 also performs well as a screening 
tool for other anxiety disorders such as post-traumatic stress disorder, panic disorder, and social 
anxiety (Kroenke, Spitzer, Williams, Monahan, & Lowe, 2007). This measure can be found in 
Appendix F.   
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2.2.7 Pain Anxiety Symptoms Scale-Short Version 
The Pain Anxiety Symptoms Scale (PASS-20; McCracken & Dhingra, 2002) is a 
condensed 20-item version of the 40-item PASS (McCracken, Zayfert, & Gross, 1992). The 
PASS-20 is a self-administered measure designed to assess FOP. Each item requires the 
respondents to rate how frequently they engage in specific thoughts and behaviors related to the 
experience of pain on a 6-point Likert-type scale that ranges from 0 (never) to 5 (always). The 
PASS-20 is divided into four 5-item subscales that measure cognitive anxiety responses, escape 
and avoidance, fearful thinking, and physiological anxiety responses. Subscale scores range from 
0-25 and total scores range from 0-100. Individuals with scores greater than 30 are classified as 
having high FOP (Abrams, Carleton, & Asmundson, 2007). The PASS-20 has shown excellent 
internal consistency (α= 0.91; Abrams et al., 2007; McCracken & Dhingra, 2002), good test-
retest reliability (r = 0.68; Coons, Hadjistavropoulos, & Asmundson, 2004), as well as 
concurrent validity with other related measures (Abrams et al., 2007). This measure can be found 
in Appendix G.   
2.2.8 Medication Use/Misuse Questionnaire 
Similar to the measure used by Meisel and Goodie (2015), respondents were asked to 
endorse whether they had a current prescription for the following non-headache medications: 
stimulants (i.e., Ritalin, Adderall, Dexedrine), opioids (not for the treatment of headache; i.e., 
Vicodin, Oxycotin, Percocet), anxiolytics (i.e., Xanax, Valium, Klonopin), and sedatives (i.e., 
Ambien, Halcion, Restoril). Prescription misuse was assessed by asking respondents to endorse 
whether they had used any of these medications without a prescription during the past 12 
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months. For each medication they endorsed misusing, participants were asked to endorse the 
average number of days per month of use. This measure can be found in Appendix H. 
2.2.9 Substance Use/Abuse Questionnaire 
Similar to the measure used by Meisel and Goodie (2015), respondents answered 
questions related to the frequency of their alcohol, tobacco, caffeine, and marijuana use during 
the past 12 months. For each substance they endorsed, frequency of use was assessed by asking 
respondents to report the average number of days per month of use. Respondents were also asked 
whether they had used cocaine, methamphetamine, ecstasy, heroin, inhalants, or hallucinogens 
during their lifetime. Additional items queried whether or not they had experienced symptoms of 
dependence and whether they or a family member had been diagnosed or treated for a substance 
use disorder. This measure can be found in Appendix I.  
2.3 Procedure 
Patients treated at Oxford Neurology Clinic consent to being contacted and having their 
data used for research purposes as part of the clinic intake procedures. Medical chart reviews 
were conducted on May, 24, 2016 by the chief neurologist in order to identify eligible 
participants treated for headache within the past six years (e.g., between March, 1, 2010 – May, 
24, 2016). Electronic records were searched using the following diagnostic terms: “drug-
induced”, “migraine”, “cluster”, “tension”, and “headache”. Between June 2016 and February 
2017, all eligible patients who had email addresses on file were emailed an invitation to 
participate in the study, and a random sample of patients without email addresses who had been 
seen in the clinic since January, 1, 2012 were sent mailed invitations to participate. Each 
invitation included a link to a computer-administered Qualtrics survey that included the 
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aforementioned measures. When eligible participants visited the link, they were provided with 
information about study procedures and associated risks and benefits. Prior to beginning the 
survey, informed consent was obtained electronically. Patients who completed the questionnaire 
received a $10 Amazon gift card for participating. Patients who reported that they no longer 
suffered from headache were excluded from the study, as were patients who had less than 80% 
complete data (in total and on each individual measure), failed to answer headache-relevant 
items, or endorsed headache resulting from head injury/trauma.    
2.7 Statistical Analysis 
Analyses were conducted with SPSS 22.0 (IBM, Inc., Chicago, IL, USA). Descriptive 
statistics are presented using frequency counts, percentages, means, and standard deviations. 
Odds ratios (ORs) with 95% confidence intervals (CIs) and p-values are also presented for 
interpretive convenience. To avoid the common problem of inflated Type 1 error rates often 
associated with analyses involving numerous predictor variables, standardized mean differences 
(SMDs; Austin, 2011) were calculated to quantify the size of any observed differences between 
MOH and non-MOH groups. Standard mean difference functions as a measure of effect size 
between groups that is calculated in relation to the two groups’ pooled variability (i.e., SD). 
Similar to Cohen’s D (Cohen, 1992), SMDs of 0.2-0.49 are interpreted as small effects, 0.5-0.79 
as medium effects, and ≥ 0.8 as large effects.   
Combined theory- and data-driven approaches were used to examine the characteristics 
independently (i.e., one predictor alone) and uniquely (i.e., after controlling for other predictors) 
associated with MOH. To reduce the potential number of predictors into discrete subsets for 
subsequent analyses, predictor variables were aggregated into five domains based on theoretical 
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consistency: 1) demographic variables, 2) headache characteristics (including pain quality, 
headache frequency, and headache-related disability), 3) psychiatric variables, and 4) headache 
medication use, and 5) substance use variables. Next, a regression classification tree selection 
strategy was utilized separately within each domain to identify the candidate predictors that best 
differentiated between those with and without MOH. For this approach, the chi-square automatic 
interaction detection (CHAID) algorithm (Kass, 1980) was used to select the optimal 
combination of candidate predictors of MOH within each domain after adjusting the required 
statistical significance by the number of candidate predictors in each domain with a Bonferroni 
correction (p-value = .05/number of predictors within domain). The CHAID algorithm was 
selected because it is a non-parametric recursive partitioning model that tests which predictor 
variables are most strongly associated with a dichotomous outcome. As such, the CHAID 
algorithm is an empirically-based means of selecting candidate predictors for inclusion in a 
multivariate model.  
Subsequently, all candidate predictors selected from each domain analysis were 
simultaneously forced into a multivariable logistic regression model with MOH status as the 
dichotomous outcome variable. The calibration of this model was assessed using a Hosmer and 
Lemeshow test, and the predictive utility was assessed using the area under the curve (AUC) of a 
calculated receiver operating characteristic curve. Because the final model was the result of 
many data-driven inferences, the 95% CIs of the parameter estimates were re-estimated for 
confirmation using bootstrapping of 500 samples of the dataset with replacement.  
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3. RESULTS 
3.1 Participant Demographics and MOH Prevalence 
Two-thousand nine hundred and fifty-three eligible patients (i.e., adults with tension-type 
headache, migraine, or cluster headache) were identified from the Oxford Neurology Clinic 
database. A total of 1,656 patients were sent invitations to participate in the study, 646 via email 
and 1,010 via mail. A total of 198 patients responded to the invitation (12.0% response rate). 
Twenty patients failed to complete the entire survey and were excluded from analyses, as were 
three patients who denied headache and 11 patients who reported headaches deriving from a 
head injury or trauma.   
The analyzed sample consisted of 164 headache patients (87.8% female) with a mean age 
of 40.14 years (SD = 13.80). The majority (82.9%) of the sample was Caucasian, 14.6% were 
African-American, 1.2% were Hispanic/Latino, 0.6% were Asian, and 0.6% identified as 
multiracial. With regard to headache diagnosis, 43 patients (26.2%) met ICHD-III criteria for 
MOH, 21 (12.8%) met criteria for CM without MOH, 6 (3.7%) met criteria for CTTH, 70 
(42.7%) met criteria for EM (34 [20.7%] without aura and 36 [22%] with aura), 23 (14%) met 
criteria for episodic tension-type headache, and 1 (0.6%) met criteria for cluster headache. On 
average, participants reported experiencing headache 12.48 days per month (SD = 8.10), and 
average headache severity for the sample was 6.42 out of 10 (SD = 1.78). Participants reported a 
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mean score of 64.44 (SD = 6.76) on the HIT-6, with 79.3 % scoring at or above the cutoff for 
very severe headache disability. 
3.2 Determinants of MOH Status 
 3.2.1 Demographic Characteristics  
 As expected, the patients who met diagnostic criteria for MOH experienced more 
headache days per month on average (20.58) in comparison to patients who did not meet criteria 
for MOH (9.60; p < .001). Table 2 displays additional demographic characteristics of the sample 
by MOH status. The two groups were evenly balanced (SMD < 0.15) on all demographics except 
age, marital status, and BMI. On average, MOH patients were five years older (43.86 vs. 38.82; 
SMD = 0.37), less likely to be married (18.6% vs. 33.9%; SMD = 0.30), and reported a greater 
BMI (32.56 vs. 28.83; SMD = 0.48) relative to the non-MOH control group. Although age, 
marital status, and BMI differentiated between the two diagnostic groups in the univariate 
analyses, none of the demographic variables were significant within the classification tree model.  
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Table 2. Participant Demographic Characteristics by MOH Status. 
Predictor MOH (N = 43) No MOH (N= 121) OR 95% CI SMD 
Age 43.86 (14.65) 38.82 (13.30)   1.03* 1.00-1.05 0.37 
Gender 
     Male 
     Female 
 
5 (11.6%) 
38 (88.4%) 
 
15 (12.4%) 
106 (87.6%) 
1.08 0.37-3.16 0.06 
Ethnicity 
     White 
     Non-white 
 
36 (83.7%) 
7 (16.3%) 
 
100 (82.6%) 
21 (17.4%) 
1.08 0.42-2.76 0.08 
Marital Status 
     Married 
     Not Married 
 
8 (18.6%) 
35 (81.4%) 
 
41 (33.9%) 
80 (66.1%) 
0.45 0.19-1.05 0.30 
Education 
     < Bachelor’s        
degree 
≥ Bachelor’s 
degree 
 
23 (53.5%) 
20 (46.5%) 
 
56 (46.3%) 
 
65 (53.7%) 
0.75 0.37-1.51 0.13 
Income 
     < $50,000 
     ≥ $50,000 
 
26 (61.9%) 
16 (38.1%) 
 
68 (56.7%) 
52 (43.3%) 
0.81 0.39-1.65 0.09 
Employment 
     Employed 
     Unemployed 
 
24 (57.1%) 
18 (42.9%) 
 
73 (60.3%) 
48 (39.7%) 
0.88 0.43-1.79 0.06 
BMI 32.56 (9.15) 28.83 (7.14) 1.06** 1.02-1.11 0.48 
 
Note. Values are frequency counts (%), except for age which is displayed as a mean (standard 
deviation). MOH = medication-overuse headache, OR = odds ratio vs No MOH group, CI = 
confidence interval, SMD = Standardized mean difference, BMI = body mass index.  
*p < .05. **p < .01. 
3.2.2 Headache Characteristics  
 Table 3 displays the headache characteristics between groups. A small effect was 
observed between groups on headache severity (SMD = 0.46) and a medium effect was observed 
in headache-related disability (SMD = 0.61). These univariate outcomes indicated that patients 
with MOH experienced more severe headaches and greater headache-related disability in 
comparison to non-MOH patients. In the classification tree, only headache-related disability 
(HIT-6) scores significantly discriminated between groups, χ2 (1) = 17.64, p < .001. Moreover, 
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the classification tree indicated that a HIT-6 score of 67 made the best distinction between the 
two groups such that individuals who obtained scores greater than 67 on the HIT-6 were more 
likely to meet criteria for MOH in comparison to individual who reported scores equal to or less 
than 67. Selection of additional predictors within this domain did not significantly improve the 
prediction afforded by headache-related disability alone.  
Table 3. Headache characteristics by MOH Status. 
Predictor MOH (N = 43) No MOH (N = 121) OR 95% CI SMD 
Headache Duration 
     < 4 hours 
     ≥ 4 hours 
 
5 (11.6%) 
38 (88.4%) 
 
29 (24%) 
92 (76%) 
2.40 0.86-6.65 0.27 
Pain Quality 
     Throbbing 
     Tight Pressure 
 
26 (60.5%) 
17 (39.5%) 
 
80 (66.1%) 
41 (33.9%) 
1.28 0.62-2.62 0.10 
Headache Location 
     Unilateral 
     Bilateral 
 
30 (69.8%) 
13 (30.2%) 
 
83 (68.6%) 
38 (31.4%) 
0.95 0.45-2.02 0.02 
Nausea 
     Yes 
     No 
 
36 (83.7%) 
7 (16.3%) 
 
88 (72.7%) 
33 (27.3%) 
1.93 0.78-4.76 0.23 
Photophobia 
     Yes 
     No 
 
41 (95.3%) 
2 (4.7%) 
 
104 (86%) 
17 (14%) 
3.35 0.74-15.16 0.26 
Phonophobia 
     Yes 
     No 
 
41 (95.3%) 
 2 (4.7%) 
 
107 (88.4%) 
14 (11.6%) 
2.68 0.58-12.32 0.21 
Aura Symptoms 
     Yes 
     No 
 
27 (62.8%) 
16 (37.2%) 
 
62 (51.2%) 
59 (48.8%) 
1.61 0.79-3.28 0.21 
Headache Severity 7.02 (1.47) 6.21 (1.83) 1.34* 1.07-1.69 0.46 
Headache Disability 
(HIT-6) 
67.60 (6.00) 63.31 (6.68) 1.12** 1.05-1.20 0.61 
Note. Values are frequency counts (%), except for headache severity and headache disability 
which are displayed as a mean (standard deviation). MOH = medication-overuse headache, OR = 
odds ratio vs No MOH group, CI = confidence interval, SMD = Standardized mean difference, 
HIT-6 = Headache Impact Test-6.  
*p < .05. **p < .01. 
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3.2.3 Psychiatric Symptoms 
 Table 4 displays scores on the self-report measures of psychiatric symptoms by 
diagnostic status. A medium-sized effect was observed on PHQ-9 (SMD = 0.64), as patients with 
MOH reported moderate levels of depressive symptomatology compared to those without MOH, 
who instead on average reported mild levels of depressive symptomatology. Furthermore, a 
small between-group difference was observed on the GAD-7 (SMD = 0.46), such that patients 
with MOH reported more severe symptoms of relative to individuals who did not meet 
diagnostic criteria for MOH. Medium differences (SMDs = 0.54-0.78) were also obtained for all 
four PASS-20 subscales. Relative to treatment-seeking patients who did not meet criteria for 
MOH, patients in the MOH group reported higher levels of cognitive anxiety (15.93 vs. 11.38), 
escape and avoidance behaviors (14.64 vs. 10.44), fearful appraisals (8.26 vs. 4.96), and 
physiological anxiety (10.49 vs. 7.33). For this domain, the PASS-20 escape and avoidance 
subscale was the only variable selected in the classification tree as a significant predictor of 
MOH status, χ2 (1) = 19.24, p < .001. The classification tree indicated that a PASS-20 escape and 
avoidance subscale score of 12 made the best distinction between the two groups.  
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Table 4. Self-reported Psychiatric Symptoms by MOH Status. 
Predictor MOH (N = 43) No MOH (N = 121) OR 95% CI SMD 
PHQ-9 Total 
Score 
12.63 (6.76) 8.31 (6.71) 1.09** 1.04-1.15 0.64 
GAD-7 Total 
Score 
9.30 (6.08) 6.55 (5.95) 1.08* 1.02-1.14 0.46 
PASS-20 Total 
Score 
50.14 (18.92) 34.11 (20.96) 1.04*** 1.02-1.06 0.78 
Cognitive 
Anxiety 
Subscale 
15.93 (6.52) 
 
11.38 (7.00) 
 
1.10** 
 
1.04-1.17 
 
0.66 
 
Escape & 
Avoidance 
Subscale 
14.64 (5.36) 
 
10.44 (6.13) 
 
1.12*** 
 
1.05-1.19 
 
0.71 
 
Fear 
Appraisal 
Subscale 
8.26 (5.62) 
 
4.96 (4.96) 
 
1.12** 
 
1.05-1.19 
 
0.64 
 
Physiological 
Anxiety 
Subscale 
10.49 (6.31) 7.33 (5.68) 1.09** 1.03-1.16 0.54 
Note. Values are displayed as a mean (standard deviation). MOH = medication-overuse 
headache, OR = odds ratio vs No MOH group, CI = confidence interval, SMD = Standardized 
mean difference, PHQ-9 = Patient Health Questionnaire-9, GAD-7 = Generalized Anxiety 
Disorder 7-Item Scale, PASS-20 = Pain Anxiety Symptoms Scale-Short Version. 
 
*p < .05. **p < .01. ***p < .001. 
3.2.4 Medication Use  
 Rates of headache medication use by diagnostic status are displayed in Table 5. None of 
the patients included in the sample reported the use of ergotamine for the treatment of headache. 
However, meaningful differences between groups were observed for the use of many of the acute 
headache medications. In comparison to non-MOH controls, patients who met diagnostic criteria 
for MOH were more likely to use NSAIDs (72.1% vs. 60.3%), opioids (25.6% vs. 11.6%), anti-
depressants (32.6% vs. 18.2%), and beta-blockers (23.3 vs. 7.4%) for the treatment of headache. 
Patients who met diagnostic criteria for MOH were also more likely to have received a Botox 
treatment within the past six months (27.9% vs. 14.0%) in comparison to non-MOH controls. A 
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medium-sized difference (SMD = 0.51) was observed for the use of combination medications 
(e.g., acetaminophen/aspirin/caffeine, codeine with acetaminophen, hydrocodone with 
acetaminophen), with 60.5% of MOH patients reporting use of these medications in comparison 
to 33.1% of patients who did not meet criteria for MOH. Of these differences, only the use of 
combination medications was selected into the classification tree to discriminate between the 
groups χ2 (1) = 9.10, p = .002. 
 
Table 5. Self-reported Headache Medication Use by MOH Status. 
Predictor MOH (N = 43) No MOH (N = 121) OR 95% CI SMD 
NSAIDs 31 (72.1%) 73 (60.3%) 1.70 0.80-3.63 0.22 
Triptans 18 (41.9%) 60 (49.6%) 0.73 0.36-1.48 0.14 
Opioids 11 (25.6%) 14 (11.6%) 2.63* 1.09-6.35 0.35 
Combination 
Medications 
26 (60.5%) 40 (33.1%) 3.10** 1.51-6.36 0.51 
Botox 12 (27.9%) 17 (14.0%) 2.37* 1.02-5.49 0.32 
Anti-depressants 14 (32.6%) 22 (18.2%) 2.17 0.99-4.78 0.31 
Beta-blockers 10 (23.3%) 9 (7.4%) 3.77** 1.41-10.05 0.45 
Anti-epileptics 14 (32.6%) 31 (25.6%) 1.40 0.66-2.99 0.14 
Note. Values are frequency counts (%). MOH = medication-overuse headache; OR = odds ratio 
vs No MOH group; CI = confidence interval; SMD = Standardized mean difference, NSAIDs = 
nonsteroidal anti-inflammatory drugs. 
*p < .05. **p < .01. 
3.2.5 Substance Use 
Rates of prescription medication use and substance use are displayed in Table 6. Very 
few patients reported the misuse of medications prescribed for the treatment of medical 
conditions other than headache. A total of four patients reported that they used opioids 
prescribed for conditions other than headache without a physician’s prescription. In addition, six 
patients reported the misuse of anxiolytics and two patients reported the misuse of sedatives. 
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Given that the rate of medication misuse was so low, between-group comparisons were not 
conducted for medication misuse variables.  
In addition to low rates of prescription medication misuse, patients included in the sample 
reported low rates of illicit drug use. The majority of patients (n = 156) reported that they had not 
used illicit substances other than marijuana at any point in their life. Of the patients who 
endorsed illicit drug use, five patients reported cocaine use, two patients reported crack cocaine 
use, three patients reported methamphetamine use, two patients reported ecstasy use, two 
patients reported inhalant use, and four patients reported hallucinogen use at some point during 
their lifetime. In terms of substance use disorder (SUD) symptomatology, three patients reported 
that they were unable to stop using substances when they wanted to and three patients reported 
that they experienced withdrawal symptoms after they stopped using a substance at some point in 
their life. Once again, between-group comparisons were not conducted for illicit substance use 
variables other than marijuana because symptoms of SUD were infrequently reported by patients 
included in the sample.  
Although medication misuse and a personal history of illicit substance use were very rare 
in the current sample, significant proportions of patients reported the prescribed use of 
medications for other medical conditions, a family history of substance abuse, and/or the use of 
alcohol, tobacco, caffeine, and cannabis. Accordingly, between-group analyses were conducted 
for prescription drug use, a family history of substance abuse, and the use of alcohol, tobacco, 
caffeine and cannabis. Small but meaningful differences (SMD = 0.20-0.28) between groups 
were observed in current prescriptions for opioids for conditions other than headache, current 
prescriptions for anxiolytics, and a family history positive for SUD. As such, patients who met 
diagnostic criteria for MOH were more likely to be prescribed opioids for pain conditions other 
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than headache (9.3 vs. 4.1%), have a current prescription for anxiolytics (30.2 vs. 17.4%), and to 
have a family member with a SUD (32.6% vs. 19.8%) in comparison to patients who did not 
meet criteria for MOH. Despite these small univariate differences, none of the substance use 
variables were independently selected as significant predictors of MOH status in the 
classification tree model.   
 
Note. Values are frequency counts (%). MOH = medication-overuse headache, OR = odds ratio 
vs No MOH group, CI = confidence interval, SMD = Standardized mean difference, Rx = 
Prescription, SUD = substance use disorder.  
3.3 Final Multivariable Model 
 Table 7 displays the three selected predictors (headache-related disability, escape and 
avoidance subscale of the PASS-20, and the use of combination medications for the treatment of 
headache) that were forced into the final multivariable model using the classification tree 
approach, along with 95% CIs as estimated through bootstrapping using 500 samples with 
replacement.  The omnibus model differentiated well between the two diagnostic groups χ2(3) = 
28.86, p <.001, and the Hosmer-Lemeshow test confirmed an absence of differences between 
Table 6. Self-Reported Substance Use by MOH Status.  
Predictor MOH (N = 43) No MOH (N = 121) OR 95% CI SMD 
Stimulant Rx 3 (7.0%) 10 (8.3%) 0.83 0.22-3.18 0.04 
Opioid Rx (not for 
Headache) 
4 (9.3%) 5 (4.1%) 2.38 0.61-9.31 0.20 
Anxiolytic Rx 13 (30.2%) 21 (17.4%) 2.06 0.92-4.61 0.28 
Sedative Rx 8 (18.6%) 14 (11.6%) 1.75 0.68-4.51 0.18 
Alcohol Use (past 12 
months) 
24 (55.8%) 75 (62.0%) 0.78 0.38-1.57 0.11 
Tobacco Use (past 12 
months) 
9 (20.9%) 27 (22.3%) 0.92 0.39-2.16 0.03 
Caffeine Use (past 12 
months) 
42 (97.7%) 112 (92.6%) 3.38 0.42-27.46 0.19 
Cannabis Use (past 12 
months) 
2 (4.7%) 11 (9.1%) 0.49 0.10-2.30 0.15 
Family History of SUD 14 (32.6%) 24 (19.8%) 1.95 0.90-4.25 0.27 
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observed and predicted participant classifications χ2(8) = 3.66, p = .887. Figure 1 graphically 
displays the predictive utility of this 3-variable model, which had an AUC = 0.78 (95% CI = 
0.71–0.86). Headache disability and the consumption of combination medications for the 
treatment of headache were uniquely associated with MOH diagnosis after controlling for the 
other predictors and after bootstrapping confirmation. Specifically, patients prescribed 
combination medications for the treatment of headache were approximately three times as likely 
to have MOH as patients who were not prescribed these medications. Likewise, odds of meeting 
diagnostic criteria for MOH increased 9% for each 1-point increase on the HIT-6. Further, the 
effect of the PASS-20 fell just short of significance after controlling for the other predictors 
included in the final model. For every 1-point increase on the PASS-20 escape and avoidance 
scale, odds of meeting diagnostic criteria for MOH increased by 7%.   
Table 7. Final Multivariable Prediction Model   
Predictor 
β 
Bootstrapped 
95% CI 
OR 95% CI p-value 
Headache Disability  
(HIT-6) 
0.09 0.17-0.21 1.09 1.01-1.18 .022 
PASS-20 Escape & 
Avoidance Score 
0.07 0.01-0.15 1.07 1.00-1.15 .051 
Combination 
Medications 
1.13 0.37-1.98 3.09 1.42-6.73 .004 
Note. Omnibus model χ2(3) = 28.86, p <.001, Hosmer-Lemeshow χ2(8) = 3.66, p = .887, 
bootstrapped estimate from 500 sample replications. β = estimated multinomial logistic 
regression coefficient, CI = confidence interval, HIT-6 = Headache Impact Test-6, PASS-20 = 
Pain Anxiety Symptoms Scale-Short Version. 
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Figure. 1. Receiver operating characteristics (ROC) curve of multivariable prediction model of 
medication-overuse headache status. Area under the curve: 0.78 (95% confidence interval 0.71-
0.86), p < .001.
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4. DISCUSSION 
The present cross-sectional analysis is among the first to examine the comparative 
importance of factors associated with MOH among treatment-seeking headache sufferers in the 
United States. In this sample, the factors most strongly associated with MOH included headache-
related disability, attempts to escape and avoid painful stimuli, and the use of combination 
medications for the treatment of headache. In conjunction, these three variables accurately 
distinguished between those with and without MOH.  
4.1 Demographic and Headache Characteristics  
Contrary to hypotheses, women were no more likely than men to meet diagnostic criteria 
for MOH. These findings suggest that demographic characteristics may not be particularly 
relevant to the identification of headache patients who are currently overusing acute pain 
medications.  Although some studies have found that women are more likely to develop MOH 
(Jonsson et al., 2011), others have suggested that the preponderance of women with MOH 
simply reflects the fact that women are much more likely than men to suffer from headache 
(Burch et al., 2015; Westergaard et al., 2014). The findings of the current study support the latter 
conclusion and suggest that headache treatment history, behavioral responses to pain, and 
psychiatric variables are more relevant in the identification of patients with medication overuse.  
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Patients with a history of migraine typically experience unilateral pulsating pain (ICHD-
IIIβ), and previous research suggests that patients with MOH typically report a history of 
migraine (Mathew, 1982; Radat et al., 2008). Although patients with TTH may also overuse 
acute headache medications, TTH is less frequently associated with MOH in comparison to 
migraine (Silberstein et al., 1996). Despite the association between migraine and MOH, pain 
quality and location frequently change following the onset of MOH (Tepper, 2012) and may 
differ by medication type (Limmroth et al., 2002). Thus, it is more difficult to identify the 
primary headache diagnosis while the patient continues to overuse acute headache medications 
(Diener, Holle, Solbach, & Gaul, 2016). In contrast to previous studies that identified headache 
characteristics and diagnoses most closely associated with the development of MOH, the current 
study examined whether headache characteristics could differentiate between patients with MOH 
and non-MOH controls. Results indicated that patients with MOH did not differ significantly 
from non-MOH controls in terms of pain location or quality. Thus, patients who report unilateral 
pulsating migraine pain may be more likely to develop MOH relative to TTH patients who report 
bilateral tightening pain; however, headache characteristics such as pain quality and location do 
not appear to reliably differentiate between patients already with MOH and those without MOH.  
4.2 Headache-Related Disability 
The finding that headache patients who met criteria for MOH were significantly more 
disabled in comparison to non-MOH control patients adds to a large body of research indicating 
that MOH is significantly more disabling than most other forms of headache (Lanteri-Minet et 
al., 2011; Linde et al., 2012; Raggi et al., 2015). In addition to previous estimates of the societal 
burden and monetary cost associated with MOH (D’Amico et al., 2005; Linde et al., 2012; Vos 
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et al., 2013), the present findings highlight the personal costs associated with MOH. Specifically, 
individuals with MOH are more likely to experience negative cognitive, social, and 
psychological outcomes in comparison to patients seeking treatment for other headache 
conditions. In the univariate analysis, individuals with MOH reported HIT-6 scores that were 
4.29 points higher on average relative to non-MOH controls. Moreover, the multivariable model 
indicated that for every 1-point increase on the HIT-6, the odds of meeting criteria for MOH 
increased by 9%, even after controlling for scores on the escape and avoidance subscale of the 
PASS-20 and the use of combination medications. Extrapolating this finding using the four 
levels of severity specified by the HIT-6, an individual who scored a 60 on the HIT-6 (e.g., “very 
severe” headache-related disability) was at approximately two times greater odds of meeting 
diagnostic criteria for MOH in comparison to an individual who scored a 49 on the HIT-6 (e.g., 
“little impact” of headache on disability). Although HIT-6 scores were associated with MOH, 
headache-related disability is conceptualized as a consequence of MOH (Linde et al., 2012) 
rather than a predictor of maladaptive medication use behaviors. Therefore, headache-related 
disability is rarely conceptualized as a risk factor for MOH. As such, the HIT-6 and other brief 
measures of headache-related disability may be most useful for identifying patients who are 
currently overusing their headache medications and for monitoring treatment progress. 
4.3 Escape and Avoidance Behaviors 
Although previous studies have indicated that repeated engagement in escape and 
avoidance behaviors in the presence of pain-related stimuli is associated with increased disability 
and the use of acute headache medications (Asmundson et al., 2001; Black et al., 2015), the 
present study is among the first study to examine FOP as a predictor of MOH using ICHD-IIIβ 
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diagnostic criteria. Patients who met diagnostic criteria for MOH were more likely to engage in 
escape and avoidance behaviors (e.g. avoiding important activities due to pain, cessation of 
activities at the first sign of pain, and taking medications at the first sign of pain) relative to 
patients with other headache conditions. Individuals with MOH obtained PASS-20 escape and 
avoidance subscale scores that were on average 4.20 points greater than those of non-MOH 
controls. Moreover, the multivariable model indicated that for every 1-point increase on the 
PASS-20 escape and avoidance subscale, the odds of meeting criteria for MOH increased by 7%, 
even after controlling for headache-related disability and the use of combination medications.  
The finding that pain-related escape and avoidance is strongly associated with MOH has 
significant clinical implications. Historically, headache patients have been advised to identify 
and avoid headache triggers (World Health Organization, 2006). Presumably, this advice is given 
under the notion that avoidance of triggers should confer reduction in headache. However, there 
is very little empirical or theoretical support for this strategy (see Martin & MacLeod, 2009). 
Instead, a prolonged pattern of escape and avoidance in response to headache triggers and 
headache pain is often maladaptive and associated with a number of negative consequences 
stemming from increased sensitivity to the avoid trigger, including increased pain, disability, and 
the excessive use and misuse of analgesics (Asmundson et al., 1999; Asmundson et al., 2001; 
Black et al., 2015; McCracken & Dhingra, 2002; Norton & Asmundson, 2004; Vlaeyen et al., 
1995). Based on these findings and psychological research in the area of stress and emotion 
regulation (Meichenbaum, 1985; Blackledge & Hayes, 2001), an emerging body of research 
suggests that progressive exposure to triggers, similar to that used for the treatment of anxiety 
disorders, is effective in reducing nociceptive response and sensitivity to headache triggers 
(Martin, 2001; Martin, Lae, & Reece, 2007; Martin, Reece, & Forsyth, 2006). In these studies, 
44 
 
individuals were exposed to commonly identified headache triggers (e.g., “visual disturbances”, 
noise, and stress) for varying durations. In all three studies, a curvilinear relationship was 
identified between the length of exposure to a trigger and sensitivity to the trigger, such that 
longer exposure produced decreased sensitivity. Based on these findings, a recent randomized 
controlled trial (RCT) found that a behavioral intervention that included graduated exposure to 
relevant headache triggers produced significant improvements in headache and reductions in 
medication consumption (Martin et al., 2014). In conjunction with these findings, the current 
study suggests that headache patients who are highly fearful of pain may engage in consistently 
avoidant patterns of behavior and are thus more likely to meet diagnostic criteria for MOH. 
Exposure-based treatment, such as that developed by Martin and colleagues (2014), may hold 
particular promise for individuals who are highly fearful of pain and patients who meet 
diagnostic criteria for MOH. Nonetheless, carefully controlled research is needed before such 
conclusions can be drawn.  
4.4 Other Psychiatric Symptoms 
Although the escape and avoidance subscale of the PASS-20 was the only psychiatric 
variable chosen for inclusion by in the classification tree, several other measures of psychiatric 
symptoms were significantly associated with MOH status in univariate analyses. As reported 
elsewhere (Hagen et al., 2012; Radat et al., 2005), anxiety and depression are associated with 
subsequent development of MOH and may serve as predictors for deleterious outcomes. 
Consistent with these findings, patients in the present study who met diagnostic criteria for MOH 
obtained scores on the PHQ-9 and GAD-7 significantly greater than those of patients without 
MOH. Though is well established that psychiatric disorders are commonly comorbid with 
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headache (Kalayadjian & Merikangas, 2008), findings of this and other studies indicate that 
psychiatric comorbidities are even more prevalent among individuals with MOH. For example, 
Radat and colleagues (2005) found that individuals suffering from MOH were more likely to 
report anxiety and mood disorders in comparison to migraineurs, and that these conditions were 
far more likely to precede than to follow MOH. As such, psychiatric conditions are 
conceptualized risk factors for MOH rather than the result of MOH. The self-medication model 
of substance use disorders (Khantzian, 1997) suggests that individuals abuse substances in an 
attempt to avoid, escape, or relieve distress evoked by negative affective states. Accordingly, 
future studies should examine to what extent this model applies to individuals with MOH and 
whether behavioral and cognitive-behavioral interventions (e.g., exposure-based interventions 
for anxiety and behavioral activation for depression) targeting anxiety and depression are 
effective for preventing the development of MOH or reducing the frequency of acute medication 
use.  
4.5 Medication Use 
As predicted, use of medications with higher potential for abuse and misuse (e.g. opioids 
and combination medications, which included those containing opioids) was associated with 
higher odds of meeting criteria for MOH. Although use of opioid medications significantly 
predicted MOH in univariate analyses, the use of combination medications was the strongest 
predictor of MOH status, and use of opioids did not improve the classification afforded by use of 
combination medications. After controlling for headache-related disability and escape and 
avoidance behaviors, patients using combination medications were still at approximately three 
times greater odds to meet the diagnostic criteria for MOH relative to patients not using these 
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medications. The current findings support the recommendation that opioids and opioid-
combination analgesics should generally not be prescribed for headache (Loder et al., 2013). All 
acute headache medications have the potential for overuse; however, headache-specific 
medications such as triptans and non-specific medications such as NSAIDS were associated with 
much lower odds (0.73 and 1.70, respectively) for MOH.  
Combination medications that contain NSAIDs have demonstrated consistent and 
impressive evidence for the treatment of migraine (Gatoulis, Voelker, & Fisher, 2012; Loder, 
2005). However, many authors suggest that opioid-combination analgesics should be used on a 
limited basis (Levin, 2014; Loder, 2005; Loder et al., 2013). Although many opioids and opioid-
combination analgesics are superior to placebo for the treatment of headache (Kelley & Tepper, 
2012; Loder, 2005), the frequent use of opioids and opioid-combination analgesics for the 
treatment of headache pain is contraindicated due to a high risk for headache chronification, pro-
nociceptive effects, tolerance, overuse, and addictive behaviors, as well as decreased 
effectiveness of other acute medications (Bigal et al., 2008; Katzung, Masters, & Trevor, 2012; 
Levin, 2014; Kelley & Tepper, 2012). For example, Bigal and colleagues (2008) documented the 
association between opioid use and the rapid progression of migraine even for minimal use. 
Similar concerns have been raised in reference to the use of opioid-combination analgesics, as 
the regular use of opioid-combination analgesics is associated with chronic headache (Scher et 
al., 2010). Accordingly, more research regarding the safety and tolerability of these drugs is 
warranted. Given the sparse evidence for efficacy and the high risk for tolerance and overuse, 
opioids and opioid-combination analgesics should only be used the treatment of headache when 
all other options have been exhausted. Practice guidelines and recommendations promote triptans 
for patients who respond poorly to NSAIDS and daily preventive medications for patients who 
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overuse their acute headache medications (Loder et al., 2013). The findings of the current study 
add to concerns regarding the efficacy and safety of combination medications as patients who 
used these medications were at a more than a three times greater risk for MOH in comparison to 
patients who did not use these medications.  
The fact that the use of opioids for the treatment of headache was not chosen for 
inclusion in the final multivariable model was unexpected and may be at least partially 
attributable to the small number of patients (n = 25) who reported the use of opioids for the 
treatment of headache. Relative to population samples that include patients treated in a variety of 
settings, patients recruited for the present study may have been less likely to receive a 
prescription for opioids because they were receiving treatment from a headache specialist 
familiar with headache treatment guidelines. Ongoing research efforts are needed to monitor and 
examine prescription practices across a wide variety of settings. Specifically, a focus on ED 
settings seems prudent as opioids remain commonly prescribed in these settings (Mazer-
Amirshahi et al., 2014; McCarthy & Cowan, 2015) and may reflect prescribers’ unfamiliarity 
with headache treatment guidelines. In addition to well-documented legislation and public health 
reform, efforts aimed at curbing the prescription of opioids for chronic pain, additional efforts 
should be aimed at making headache treatment guidelines readily available in ED settings.  
4.6 Substance Use 
Contrary to expectations, substance use and prescription misuse were relatively 
uncommon and did not differentiate between patients who met diagnostic criteria for MOH and 
those who did not. The relationship between MOH and problematic substance use is unclear and 
complex. Medication overuse headache has previously been depicted as a part of a broader 
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pattern of substance abuse and addictive behaviors (Radat et al., 2008; Radat et al., 2005). 
Patients with MOH have exhibited higher rates of abuse and misuse of substances such as 
tobacco, caffeine, sedatives, and anxiolytics; however, only a small percentage of individuals 
reported problematic alcohol use or illicit drug use (Hagen et al., 2012; Radat et al., 2008; Radat 
et al., 2005). In light of the current findings and findings drawn from previous research, the 
function of substance use and medication misuse behaviors should be examined further among 
individuals with headache. Although some headache patients may engage in problematic 
substance use and medication misuse with the goal of “getting high”, it may be the case that the 
majority of headache patients overuse analgesics and use other substances in an attempt to self-
medicate headache pain and psychiatric distress. The finding that there was no association 
between MOH and problematic alcohol use or illicit drug use is consistent with previous findings 
(Hagen et al., 2012; Westergaard et al., 2016). A significant proportion of headache patients 
abstain from alcohol (Panconesi, Franchini, Bartolozzi, Magnai, & Guidi, 2013), possibly 
because alcohol is among the most commonly identified dietary headache triggers (Kelman, 
2007). Despite these findings, medication class should be examined a moderator of this 
relationship. A large number of patients included in the present study overused over-the-counter 
medications, but problematic substance use has been documented most extensively among 
chronic pain patients who misuse opioids (Ives et al., 2006).  
4.7 Limitations and Future Directions 
 Strengths of the current study included the examination of a treatment-seeking sample of 
headache patients, the consideration of relevant MOH risk factors in conjunction, and the use of 
a conservative and empirical approach designed to avoid Type I error inflation when selecting 
49 
 
variables for the final multivariable model. Despite these strengths, some limitations are worth 
bearing in mind. First, the present study was cross-sectional; therefore, significant associations 
between variables should be interpreted as correlational rather than causal due to uncertainty 
regarding the temporal ordering of variables. For example, it is assumed that psychiatric 
symptoms predict medication overuse (Radat et al., 2005; Schmid et al. 2013) and negatively 
influence pain coping abilities (Asmundson et al., 2001; Black et al., 2015). However, we did not 
assess order of occurrence, and psychiatric symptoms could develop or worsen subsequent to the 
overuse of acute headache medications. The temporal ordering of variables has significant 
theoretical implications as the function of medication overuse is often ignored. Based on 
theoretical models such as the fear-avoidance model of chronic pain (Vlaeyen & Linton, 2000) 
and the self-medication model of substance use disorders (Khantzian, 1997), headache patients 
who overuse their medications may do so in an attempt to avoid pain and feared pain-related 
stimuli or to self-medicate symptoms of anxiety and depression. However, causality cannot be 
assumed until this study is replicated longitudinally. Studies that concurrently monitor headache 
frequency, medication use, psychiatric symptoms, and other medical and psychosocial variables 
over time would provide valuable data related to the directionality and causality of relationships 
between variables and could inform the development of future assessment measures and 
intervention efforts.  
Second, though the sample was unique in that it was composed of individuals seeking 
treatment for headache, patients were all treated by the same physicians and drawn from a 
limited geographic area. Despite this limitation, the rate of MOH in the present study 
(approximately 26%) closely resembles that from previous studies (Schmid et al., 2013). 
Individuals who met criteria for MOH also reported 20.58 (SD = 5.39) headache days per month 
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on average and were very severely impaired due to headache pain. Thus, the nature of their 
headache characteristics also closely resemble treatment-seeking samples used in previous 
studies (Schmid et al., 2013; Usai, Grazzi, D’Amico, Andrasik, & Bussone, 2008). In 
conjunction, the similarity between the present and prior samples increases confidence that the 
current findings are likely generalizable to clinical samples of headache patients. Nonetheless, 
replication efforts are needed with more diverse patients drawn from a variety of locations and 
clinics.  
Third, assessment of substance use and medication misuse was limited in two ways. First, 
substance use and medication use variables were based solely on self-report, and biological 
measures were not collected. As part of informed consent, patients were instructed that their 
responses would remain entirely confidential and would not impact the treatment that they 
received from their healthcare provider. Nonetheless, patients may have been reluctant to 
disclose information related to the use of illicit substances or the misuse of prescription 
medications. Second, in order to reduce the burden on participants and increase participation in 
the study, a large number of headache medications were collapsed into a smaller number of 
categories. For example, combination medications consisted of over-the-counter medications 
such as Excedrin and highly potent opioid-combination medication such as Lortab. Given the 
risks associated with the use of opioids for headache (Levin, 2014), there are likely to be 
differences between individuals who overuse acetaminophen combinations and individuals who 
overuse opioid-combination medications. Thus, future studies should consider more precise and 
specific definitions of medication class and utilize biological markers of illicit drug use and 
prescription medication misuse.  
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Finally, low base rates of medication misuse and substance abuse limit the conclusions 
that can be drawn with regard to the relation between these specific agents and MOH. Similarly, 
univariate analyses did not reveal any significant interactions between examined variables. 
Sample size constraints may have prohibited the assessment of interactive effects with sufficient 
power. Despite the absence of significant interaction effects with this class of predictors, the 
CHAID algorithm afforded valuable empirically-based decisions regarding which variables to 
include in the multivariate model. Statistical approaches similar to CHAID algorithm 
implemented in the present study may prove useful in the development of brief screening 
measures that can be readily administered in busy primary care and emergency care settings. 
Such measures could endeavor to include the three variables retained in the final multivariable 
model herein and could also be helpful for identifying patients who would benefit from 
preventive treatment efforts.  
In summary, the current study is a first step in an effort to more effectively identify and 
treat headache patients who are overusing prescription pain medications. Based on these 
findings, a relatively focused number of variables can be assessed to identify patients most likely 
to meet diagnostic criteria for MOH. Although a great deal of research has been aimed at 
developing screening measures to identify patients at risk for opioid abuse and misuse in broader 
populations (Butler, Budman, Fernandez, Franciullo, & Jamison, 2009; Butler, Budman, 
Fernandez, & Jamison, 2004; Webster & Webster, 2005), MOH has received less attention. 
Future studies may build on the present study by applying similar analytic approaches 
longitudinally in order to identify headache patients at risk for medication overuse prior to the 
onset of maladaptive medication use behaviors. In addition to the development of screening 
measures, the findings that escape and avoidance behaviors were strongly predictive of MOH has 
52 
 
significant clinical implications as headache patients are often instructed to avoid headache 
triggers whenever possible. Future research should also examine whether exposure-based 
treatments that facilitate engagement with headache triggers and other feared headache stimuli 
can reduce the risk for MOH and whether previously developed interventions (Martin et al., 
2014) can be modified and abbreviated for effective implementation in clinical settings where 
these challenging patients are commonly treated.   
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DEMOGRAPHIC QUESTIONNAIRE 
 
Please tell us a little bit about yourself. This information is of course completely confidential. 
 
How old are you (in years)?:__________ 
 
Gender:__________ (male/female/trans) 
 
Race: (check one) 
 ______ Caucasian 
 ______ Black/African-American 
 ______ Hispanic/Latino 
 ______ Asian 
______ Asian or Pacific Islander 
______ Native American or Alaskan Native 
______ Native Hawaiian or Pacific Islander 
 ______ Multiracial 
 
What was your highest level of education? (check one) 
 ______ 8th grade or less 
______ some high school 
 ______ high school diploma 
 ______ some college/university 
 ______ bachelor’s degree 
 ______ master’s degree 
______ doctoral or professional degree 
 
Marital status: (check one) 
 ______ single (never married) 
 ______ married 
 ______ divorced 
______ separated 
 ______ widowed 
 
Employment status: (check one) 
 ______ unemployed 
 ______ home maker 
 ______ part time 
 ______ full time 
 
Yearly household income: (check one) 
 ______ < $10,000 
 ______ $10,000 - $20,000 
 ______ $21,000 - $30,000 
 ______ $31,000 - $50,000 
 ______ $51,000 - $100,000 
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 ______ >$100,000 
  
How tall are you? (in feet AND inches): ______Feet & ______Inches 
How much do you weigh (in pounds)?: _____Pounds 
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STRUCTURED DIAGNOSTIC INTERVIEW FOR HEADACHE – 3 
 
1. Do you ever get headaches? 
 a. Yes  b. No 
 
2. On average, how many DAYS PER MONTH do you have a headache (enter one number 
between 0 and 30)? 
 _____ days per month with headache 
 
3. If 0 is no pain, 5 is moderate pain, and 10 is the worst pain imaginable, what is the average 
pain intensity of these headaches (enter one number between 0 and 10)? 
_____ average pain intensity 
 
4. If left untreated or unsuccessfully treated, about how long would these headaches usually last? 
a. less than 30 minutes 
b.at least 30 minutes but less than 2 hours 
c.at least 2 hours but less than 4 hours 
d. between 4 hours and 3 days 
e. between 3 days and 7 days 
f. longer than 7 straight days 
 
5. For approximately how long have you been having these headaches?  
 a. Less than 3 months 
 b. 3 months 
 c. 4 months or more 
 
6. About how many of these headaches have you had in your life? 
 a. Less than 5 
 b. 5 – 9 
 c. 11 – 20 
 d. More than 20 
 
7. Which of the following best describes your pain? 
 a. Pulsating/Throbbing b. Tight pressure (non-pulsating) 
 
8. Is the pain typically experienced on one side or both sides of your head? 
 a. Typically one side  b. Typically both sides 
 
9. Is the pain made worse by routine physical activities or cause you to avoid routine physical 
activities (like walking, bending over, or climbing stairs)?  
 a. Yes  b. No 
 
10. Do you often feel nauseous or sick to your stomach during these headaches? 
 a. Yes  b. No 
 
11. Do you often vomit or throw up during these headaches? 
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 a. Yes  b. No 
 
12. Are you often sensitive to light during these headaches? 
 a. Yes  b. No 
 
13. Are you often sensitive to sound during these headaches? 
 a. Yes  b. No 
 
14. Do you often experience any symptoms shortly before the headache pain actually begins, 
such as changes in your vision (blurry vision, seeing spots or zigzag lines), changes in your 
sensation (numbness, tingling), or changes in your speech? 
 a. Yes 
 b. No  
 
15. How many times have you experienced these symptoms before having a headache? 
 a. 1 
 b. 2 – 5 
 c. 6 – 10 
 d. More than 10 
 
16. Do you use any medications to treat these headaches? 
 a. Yes 
 b. No 
 
17. How many days per week do you use any type of medication to treat your headaches? 
 a. Less than 1 day per week 
 b. 1-2 days per week 
 c. 3 days per week 
 d. 4 or more days per week 
 
18. How long have you been using these medications at this frequency? 
 a. 3 months or less 
 b. More than 3 months 
 
19. Did your headache develop or get worse when you started using these medications at this 
frequency? 
 a. Yes 
 b. No 
 
20. Did this headache develop shortly after a head injury or head trauma? 
 a. Yes 
 b. No 
 
21. Have you ever been diagnosed with cluster headaches? 
 a. Yes 
 b. No 
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HEADACHE MEDICATION USE QUESTIONNAIRE  
1. Are you currently taking NSAIDS or simple analgesics (e.g. aspirin [Bayer, Excedrin], 
ibuprofen [Advil, Motrin], naproxen sodium [Aleve], Anaprox) for the treatment of your 
headaches? 
a. How many days during the previous month did you use NSAIDS or simple analgesics for 
the treatment of your headaches? 
b. How long have you used NSAIDS or simple analgesics at this frequency? 
 
2. Are you currently taking ergotamine for the treatment of your headaches? 
a. How many days during the previous month did you use ergotamine for the treatment of 
your headaches? 
b. How long have you used ergotamine at this frequency? 
 
3. Are you currently taking triptans (e.g. sumatriptan [Imitrex], naratriptan [Amerge], 
zolmitriptan [Zomig], rizatriptan [Maxalt], almotriptan [Axert], frovatriptan [Frova], 
eletriptan [Relpax]) for the treatment of your headaches? 
a. How many days during the previous month did you use triptans for the treatment of your 
headaches? 
b. How long have you used triptans at this frequency? 
 
4. Are you currently taking opioids (e.g. codeine, hydrocodone, merperdine [Demerol], 
oxycodone [Oxy IR], dilaudid, morphine) for the treatment of your headaches? 
a. How many days during the previous month did you use opioids for the treatment of your 
headaches? 
b. How long have you used opioids at this frequency? 
 
5. Are you currently taking combination medications (e.g. acetaminophen/aspirin/caffeine 
[Excedrin Migraine, BC Powder, Goody’s Powder], codeine with acetaminophen [Tylenol 
#3], hydrocodone with acetaminophen [Lortab, Vicodin], merperdine with promethazine 
[Mepergan], oxycodone with aspirin [Percodan], oxycodone with acetaminophen [Percocet] 
for the treatment of your headaches? 
a. How many days during the previous month did you use combination medications for the 
treatment of your headaches? 
b. How long have you used combination medications at this frequency? 
 
6. Are you currently taking antidepressants (e.g. amitriptyline [Elavil], venlafaxine [Effexor]) for 
the treatment of your headaches? 
a. How many days during the previous month did you use antidepressants for the treatment 
of your headaches? 
b. How long have you used antidepressants at this frequency? 
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7. Are you currently taking antiepileptic drugs (e.g. divalproex sodium [Depakote], sodium 
valproate [valproate], topiramate [Topamax]) for the treatment of your headaches? 
a. How many days during the previous month did you use antiepileptic drugs for the 
treatment of your headaches? 
b. How long have you used antiepileptic drugs at this frequency? 
 
8. Are you currently taking beta-blockers (e.g. metoprolol [Lopressor], propranolol [Inderal], 
timolol [Timoptic]) for the treatment of your headaches? 
a. How many days during the previous month did you use beta-blockers for the treatment of 
your headaches? 
b. How long have you used beta-blockers at this frequency? 
 
9. Have you received onabotulinumtoxinA [Botox] within the past 6 months for the treatment of 
your headaches?  
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PATIENT HEALTH QUESTIONNAIRE-9   
(PHQ-9)  
Over the last 2 weeks, how often have you been bothered by 
any of the following problems? (Use “✔” to indicate your 
answer)  Not at all  
Several 
days  
More 
than half 
the days  
Nearly 
every 
day  
1. Little interest or pleasure in doing things  0  1  2  3  
2. Feeling down, depressed, or hopeless  0  1  2  3  
3. Trouble falling or staying asleep, or sleeping too much  0  1  2  3  
4. Feeling tired or having little energy  0  1  2  3  
5. Poor appetite or overeating  0  1  2  3  
6. Feeling bad about yourself — or that you are a failure or have let 
yourself or your family down  
0  1  2  3  
7. Trouble concentrating on things, such as reading the newspaper or 
watching television  
0  1  2  3  
8. Moving or speaking so slowly that other people could have 
noticed?  Or the opposite — being so fidgety or restless that you 
have been moving around a lot more than usual  
0  1  2  3  
9. Thoughts that you would be better off dead or of hurting yourself 
in some way  
0  1  2  3  
                                                                                                              FOR OFFICE CODING     0      + ______  +  ______  +  ______  
=Total Score:  ______           
 
If you checked off any problems, how difficult have these problems made it for you to do your work, take care 
of things at home, or get along with other people?  
Not difficult  at 
all  
Somewhat  difficult  Very  difficult  Extremely  
difficult   
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GAD-7 ANXIETY      
 
Column totals:                  ___     +     ___      +   ___     +        ___     
=   Total Score _____   
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
Not difficult  
at all 
Somewhat 
 difficult 
Very 
difficult 
Extremely 
difficult  
    
 
From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD PHQ). The PHQ was 
developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues. For research information, contact Dr. 
Spitzer at rls8@columbia.edu. PRIME-MD® is a trademark of Pfizer Inc. Copyright© 1999 Pfizer Inc. All rights reserved. 
Reproduced with permission 
  Over the last 2 weeks, how often have you   
  been bothered by the following problems? 
    (Use “✔” to indicate your answer” 
Not  
at all 
Several 
days 
More than 
half the 
days 
Nearly 
every day 
1.  Feeling nervous, anxious or on edge 0 1 2 3 
2.  Not being able to stop or control worrying 0 1 2 3 
3.  Worrying too much about different things 0 1 2 3 
4.  Trouble relaxing 0 1 2 3 
5.  Being so restless that it is hard to sit still 0 1 2 3 
6.  Becoming easily annoyed or irritable 0 1 2 3 
7.  Feeling afraid as if something awful  
     might happen 
0 1 2 3 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX G: PAIN ANXIETY SYMPTOMS SCALE-SHORT VERSION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
PASS – 20  
Individuals who experience pain develop different ways to respond to that pain.  We would like 
to know what you do and what you think about when in pain.  Please use the rating scale below 
to indicate how often you engage in each of the following thoughts or activities.    
Circle one number from 0 (NEVER) to 5 (ALWAYS) for each item.    
                        NEVER            ALWAYS  
1.  I think that if my pain gets too severe, it will never decrease. 0 1 2 3 4 5 
2.  When I feel pain, I am afraid that something terrible will 
happen. 
0 1 2 3 4 5 
3.  I go immediately to bed when I feel severe pain. 0 1 2 3 4 5 
4.  I begin trembling when engaged in activity that increases 
pain. 
0 1 2 3 4 5 
5.  I can’t think straight when I am in pain. 0 1 2 3 4 5 
6.  I will stop any activity as soon as I sense pain coming on. 0 1 2 3 4 5 
7.  Pain seems to cause my heart to pound or race. 0 1 2 3 4 5 
8.  As soon as pain comes on, I take medication to reduce it. 0 1 2 3 4 5 
9.  When I feel pain, I think that I may be seriously ill. 0 1 2 3 4 5 
10.  During painful episodes, it is difficult for me to think of 
anything else besides the pain. 
0 1 2 3 4 5 
11.  I avoid important activities when I hurt. 0 1 2 3 4 5 
12.  When I sense pain I feel dizzy or faint. 0 1 2 3 4 5 
13.  Pain sensations are terrifying. 0 1 2 3 4 5 
14.  When I hurt I think about the pain constantly. 0 1 2 3 4 5 
15.  Pain makes me nauseous (feel sick to my stomach). 0 1 2 3 4 5 
16.  When pain comes on strong I think I might become 
paralyzed or more disabled. 
0 1 2 3 4 5 
17.  I find it hard to concentrate when I hurt. 0 1 2 3 4 5 
18.  I find it difficult to calm my body down after periods of 
pain. 
0 1 2 3 4 5 
19.  I worry when I am in pain. 0 1 2 3 4 5 
20.  I try to avoid activities that cause pain. 0 1 2 3 4 5 
 
 
 Thank you for completing this questionnaire.  
It will help us to better understand your pain problem.   
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MEDICATION USE/MISUSE QUESTIONNAIRE 
As you answer the following questions pertaining to medication use, medication misuse, and 
substance use, please keep in mind that all of your data will remain entirely confidential. 
 
1.) Do you currently have a prescription for a stimulants (e.g. Ritalin, Adderall, Dexedrine)? 
a. On average, how frequently have you used stimulants (e.g. Ritalin, Adderall, 
Dexedrine) prescribed to you during the past 12 months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
2.) Do you currently have a prescription for opioids NOT for the treatment of headache (e.g. 
Vicodin, Oxycotin, Percocet) 
a. On average, how frequently have you used opioids (e.g. Vicodin, Oxycotin, 
Percocet) prescribed to you during the past 12 months? (Do NOT count opioids 
used for headache) 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
3.) Do you currently have a prescription for anxiolytics (e.g. Xanax, Valium, Klonopin) 
a. On average, how frequently have you used anxiolytics (e.g. Xanax, Valium, 
Klonopin) prescribed to you during the past 12 months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
4.) Do you currently have a prescription for sedatives (e.g. Ambien, Halcion, Restoril) 
a. On average, how frequently have you used sedatives (e.g. Ambien, Halcion, 
Restoril) prescribed to you during the past 12 months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
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4. Once a week 
5. Multiple times a week 
6. Daily 
 
5.) Have you used stimulants (e.g. Ritalin, Adderall, Dexedrine) WITHOUT a physician’s 
prescription during the past 12 months?  
a. On average, how frequently have you used stimulants (e.g. Ritalin, Adderall, 
Dexedrine) WITHOUT a physician’s prescription during past 12 months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
6.) Have you used opioids not for the treatment of headache (e.g. Vicodin, Oxycotin, Percocet) 
WITHOUT a physician’s prescription during the past 12 months? 
a. On average, how frequently have you used opioids not for the treatment of 
headache (e.g. Vicodin, Oxycotin, Percocet) WITHOUT a physician’s 
prescription during past 12 months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
7.) Have you used anxiolytics (e.g. Xanax, Valium, Klonopin) WITHOUT a physician’s 
prescription during the past 12 months? 
a. On average, how frequently have you used anxiolytics (e.g. Xanax, Valium, 
Klonopin) WITHOUT a physician’s prescription during past 12 months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
8.) Have you used sedatives (e.g. Ambien, Halcion, Restoril) WITHOUT a physician’s 
prescription during the past 12 months? 
a. On average, how frequently have you used sedatives (e.g. Ambien, Halcion, 
Restoril) WITHOUT a physician’s prescriptions during past 12 months? 
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1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
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SUBSTANCE USE/ABUSE QUESTIONNAIRE 
1.) Have you used alcohol during the past 12 months? 
a. On average, how frequently have you consumed alcohol during past 12 
months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
2.) Have you used tobacco during the past 12 months? 
a. On average, how frequently have you used tobacco during past 12 months?  
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
3.) Have you consumed caffeine during the past 12 months? 
a. On average, how frequently have you consumed caffeine during past 12 
months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
4.) Have you used marijuana/cannabis during the past 12 months? 
a. On average, how frequently have you used marijuana/cannabis during past 12 
months? 
1. Not in the past year 
2. Less than once a month 
3. Once a month 
4. Once a week 
5. Multiple times a week 
6. Daily 
 
5.) Please indicate whether you have used any of the following substances during your 
lifetime:  
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a. “Powder” cocaine 
b.  “Crack” cocaine 
c. Methamphetamines (Meth) 
d. Ecstasy (other “club” drugs) 
e. Heroin 
f. Inhalants (cleansers, paint, etc.) 
g. Hallucinogens 
 
6.) Have you found yourself unable to stop using any of the aforementioned drugs when 
you wanted to?  
 
7.) Have you ever experienced withdrawal symptoms (felt sick) when you stopped taking 
any of the aforementioned drugs? 
 
8.) Have you ever been diagnosed with a substance use disorder (e.g. alcohol abuse, drug 
abuse, alcohol dependence, or drug dependence) or treated substance use? 
 
9.) Has anyone in your immediate family ever been diagnosed with a substance use 
disorder (e.g. alcohol abuse, drug abuse, alcohol dependence, or drug dependence) or 
treated for substance use. 
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